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ABSTRACT
CELLULAR MECHANISM OF ARGLABINDIMETHYLAMINOHYDROCHLORIDE CYTOTOXICITY
Xiaofei Qin
Old Dominion University and Eastern Virginia Medical School, 2006
Director: Dr. Christopher J. Osgood

Cancer is the second leading killer in the United States. Anticancer drug
development is always based on the understanding of molecular and cellular mechanisms
of carcinogenesis, as well as comprehensive knowledge of potential anticancer drugs.
Arglabin-dimethylaminohydrochloride (arglabin-DMA) represents one of the new classes
o f anti-cancer agents that have shown promise in suppressing the growth of various
tumor cells. However, the cellular mechanism of arglabin-DMA cytotoxic effects on
tumor cells is still unclear. The current study was to determine the famesyltransferase
(FTase) inhibitory activity o f arglabin-DMA and to investigate the effects of arglabinDMA on three proteins: Ras, Rho and cyclin kinase inhibitor p 2 1/WAF1/CIP1.
In vitro FTase assays were used to study the effect o f arglabin-DMA on FTase
activity. The FTase assay using expressed FTase showed that the 50% inhibition
concentration of arglabin-DMA was 2.9 mM. The FTase assay using lysates of Ras/3T3
cells that had been incubated with arglabin-DMA showed that the highest FTase
inhibition was 59% as compared to the no treatment control, and this inhibition plateaued
when the arglabin-DMA concentration was 100 nM or higher. These results suggested
that arglabin-DMA was transformed in cells and that the transformed arglabin-DMA
inhibited FTase activity in Ras/3T3 cells. However, this inhibition was limited by the
substrate availability in cells that may transform arglabin-DMA to an FTase inhibitor.
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The study o f the effects of arglabin-DMA on Ras protein, Rho protein, and cyclin
kinase inhibitor p21 /WAF1/CIP1 was performed using Ras/3T3 cells incubated with
arglabin-DMA or FTI-277 (positive control) for 24 or 72 hours. Western blots and
densitometry showed a decreased ratio of processed to unprocessed H-Ras protein in cell
lysates incubated with 100 pM of arglabin-DMA. Western blotting of active H-Ras
protein from GTPase pull-down assays showed significant reduction of active H-Ras
after incubation with 50 pM of arglabin-DMA for 24 hours, or 1 pM of arglabin-DMA
for 72 hours. Only unprocessed RhoA was detected by Western blot after incubation with
10 pM (or higher) arglabin-DMA or FTI-277. Western blots showed a trend of increased
p21/WAFl/CIPl production after 72 hours of incubation with arglabin-DMA and this
increase was not found in the FTI-277 control.
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1
INTRODUCTION

RAS PROTEINS AND ASSOCIATED SIGNAL TRANSDUCTION PATHWAY
Ras genes encode a family of GTP-binding proteins (p21 Ras) known to play major
roles in controlling cell growth and differentiation (55). Three genes encode four
isoforms o f Ras protein: H-Ras, N-Ras, Ki-Ras4A and Ki-Ras4B. Ki-Ras4A and KiRas4B are splice variants of the same gene (61, 67). H-Ras mutations are primarily found
in carcinomas o f the bladder, kidney, and thyroid. N-Ras mutations are primarily found in
myeloid and lymphoid disorders, liver carcinoma, and melanoma. Ki-Ras mutations
predominate in colon and pancreatic carcinomas (61).
Cycling between the active GTP-bound form and inactive GDP-bound form, p21 Ras
protein acts as a regulatory switch in cell signaling. In normal cell signaling, inactivation
of p21 Ras protein occurs through hydrolysis of bound GTP to GDP by the protein’s
intrinsic GTPase activity coupled with strong stimulation by GTPase-activating protein
(GAP) (47, 55). Both normal and oncogenic forms of Ras protein share similar GTP/GDP
binding properties, however, they differ in their ability to hydrolyze bound GTP. The
weak GTPase activity o f normal Ras protein is reduced approximately tenfold further in
the oncogenic Ras protein. Moreover, the oncogenic forms of Ras protein are insensitive
to GAP which functions to accelerate the slow intrinsic rate of GTP hydrolysis by normal
Ras protein. The most frequently detected alterations in oncogenes in both animal tumor
model systems and in human cancers are mutations in the ras family of oncogenes, which
includes single point mutations at codons 12, 13, 61, or 117, or by alteration of mRNA

The journal model is M olecular and Cellular Biology.
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2
splicing. Specific mutations in the ras gene impair GTPase activity and response to GAP
o f p21 Ras protein, rendering it constituitively active and resulting in uncontrolled cell
growth and morphologic transformation o f normal cells.
The Ras system is a ubiquitous signal transduction pathway that is part of the signal
transduction system for multiple tyrosine kinase receptors such as those for the epidermal
growth factor (EGF), platelet-derived growth factor (PDGF), and fibroblast growth factor
(FGF) (Fig. 1) (27, 55). When a ligand binds its receptor, receptor dimerization occurs,
triggering an autophosphorylation event and an interaction with “adaptor” proteins called
Grb2 and Sos. Grb2 complexes with the tyrosine kinase receptor and the Sos protein via
the Src protein homology domains called SH2 and SH3, respectively. Grb2 SH3 domains
bind to proline-rich sequences present in Sos, allowing recruitment of Sos to the plasma
membrane where Ras is bound. Sos activates Ras, and this activation results in release of
GDP and binding of GTP. The activated Ras complexes with Raf protein, and this
binding can induce a conformational change in Raf that activates its kinase activity.
Activated Raf then phosphorylates a second kinase called MEK (mitogen-activated
protein kinase kinase or MAPKK). MEK phosphorylates and thereby activates a third
kinase, MAP kinase (MAPK), which has among its substrates various transcription
factors such as Jun/Fos (AP-1) that regulate gene expression (27, 55, 63). This “kinase
cascade” is a crucial signaling pathway regulating growth and differentiation in many cell
types (Fig. 1).
In order for Ras protein to transduce its normal or oncogenic signal, it must be
anchored to cell membranes, which include plasma membrane, endoplasmic rediculum
(ER) membrane, and Golgi membrane (16, 17, 51). This process is accomplished by
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FIG. 1. Ras signal transduction pathway. Activated Ras protein (GTP-Ras) transfers
signals through Raf, MEK, and MAP kinase protein, which then enter the nucleus and
activate transcription factors of different genes (27, 55).
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4
a series o f post-translational modifications, including three steps: prenylation in the
cytosol, protease digestion, and methylation. The prenylated product is a substrate for
additional modifications: the terminal three amino acids are proteolyzed by enzymes to
generate a new C terminus and the new C terminus is carboxymethylated on the ER by
prenylcysteine carboxyl methyltransferase (pcCMT) (17, 42). N-Ras and H-Ras are
further modified with palmitate moieties that are attached to one or two cysteines just
upstream of the CAAX motif (17, 59). In the case of K-Ras, a polybasic sequence near
the C terminus allows stable interaction with anionic phospholipids at the inner leaflet of
the plasma membrane (2, 17). The first and rate-limiting step is prenylation that increases
the hydrophobicity o f Ras protein.

RHO PROTEINS AND ASSOCIATED PATHWAY
The Rho family o f proteins in mammals comprises several members including
RhoA, RhoB, RhoC, Racl, Rac2, and Cdc42. Rho proteins transduce signals from plasma
membrane receptors and control many cell functions requiring the assembly and
organization of the actin cytoskeleton, such as those involved in cell polarity, motility,
adhesion, cellular transformation, and apoptosis (5,21, 36). The means by which
prenylation affects interaction with membrane targets and/or regulatory proteins remain
largely unknown.
Several features distinguish RhoB from other Rho proteins (24): first, its cellular
localization in early endosomes and prelysosomal compartments is different from other
members of the Rho protein family. Secondly, RhoB is an immediate early response gene
that is induced by platelet-derived growth factor (PDGF), transforming growth factor-a
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(TGF- a), the non-receptor tyrosine kinase v-Src, and ultraviolet irradiation in fibroblasts.
Whether RhoB is also an immediate early response gene in human cancer cells is not
known. Third, RhoB mRNA and protein levels turn over much more rapidly (half-lives of
20 and 120 minutes, respectively) (42) than other GTPases, which typically have halflives on the order o f 24 hours (5, 33). Therefore, although RhoA and RhoB share 90%
amino acid sequence homology, their physiological functions are predicted to be distinct.
The level o f RhoB is maximal during the S phase of DNA synthesis and declines at S/G2M transition. Finally, Rho proteins are singly geranylgeranylated with the exception of
RhoB and RhoE. The latter two proteins can be either famesylated or geranylgeranylated
(4, 5).
RhoA is located primarily in the cytosol, with a small fraction being detected in the
plasma membrane (17). A large number of GTPase activating proteins (GAPs) can
stimulate the intrinsic GTPase activity o f RhoA. RhoA regulates signal transduction
pathways linking plasma membrane receptors to the assembly of focal adhesion and actin
stress fibers. The nucleotide sequence of the rhoA gene predicts a protein of 193 amino
acid residues. The molecular weight o f RhoA is 21,769 daltons. The amino acid sequence
of RhoA protein is 30% identical to H-Ras protein and differs from RhoB protein at the
amino acid position 29. The protein contains four highly conserved regions required for
binding guanine nucleotide and has a C-terminal CAAX box, -CLVL, which is the signal
for post-translational modification (17). A geranylgeranyl group is present at the carboxy
terminus after post-translational modification. CAAX boxes ending in leucine are
substrates for geranylgeranylation but not famesylation. Post-translationally modified
RhoA, either GDP- or GTP-bound, will form a complex with Rho-GDI (GDP
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dissociation inhibitor) and this complex is insensitive to GAP proteins. Inhibition of
RhoA in SWISS 3T3 cells has been reported to block the cell cycle in G1 (72).

CYCLIN KINASE INHIBITOR P21/WAF1/CIP1
The tumor suppressor p53 transcriptionally activates a number of genes including the
WAF1/CIP1 gene. The activation of WAF1/CIP1 by p53 appears to be key to the action
of p53 as a tumor suppressor. The WAF1/CIP1 gene promoter contains a p53 response
element. This gene encodes a 21-kD protein that binds cyclin dependent kinases (CDKs)
and arrests cells in G1 or G2 phase of cell cycle (54, 62).
The 21-kD protein of the WAF1 gene is found in a complex involving cyclins,
CDKs, and proliferating cell nuclear antigen (PCNA) in normal cells but not transformed
cells and appears to be a universal inhibitor of CDK activity. One consequence of
p21/WAFl binding to and inhibiting CDKs is the prevention of CDK-dependent
phosphorylation and subsequent inactivation of the retinoblastoma (Rb) protein that is
essential for cell cycle progression (31). P21/WAF1 is, therefore, a potent and reversible
inhibitor o f cell cycle progression at both the G1 and G2 check points, presumably to
allow sufficient time for DNA repair to be completed (26, 31).

PROTEIN FARNESYLTRANSFERASE AND PRENYLATION
Prenylation represents one of the most common lipid modifications of proteins.
Some o f the known substrates for prenylation include all p21 Ras proteins, nuclear lamin
A and lamin B, transducin y-subunit, Ras related Rho and Rac proteins, and y-subunits of
heterotrimeric G proteins (8, 23, 25, 28, 75). Protein prenylation involves C-terminal
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addition o f C 15 (famesyl) or C20 (geranylgeranyl) isoprenoids (Fig. 2). Both isoprenoids
are intermediates in cholesterol biosynthesis. Protein prenylation reactions are carried out
by one o f three enzymes in the cell: famesyltransferase (FT or FTase),
geranylgeranyltransferase type I (GGT-I or GGTase-I), or geranylgeranyltransferase type
II (GGT-II, GGTase-II or RalbGGT). FT and GGT-I are related heterodimeric enzymes
that share a common a-subunit. Prenylation at the carboxyl-terminal residues of proteins
terminating with a CAAX sequence (where C is cysteine, A is an aliphatic acid and X is
any amino acid) involves attachment of either famesyl (Cl 5) or geranylgeranyl (C20)
isoprenoids, which can facilitate the integration of the protein into membranes (25).
Famesyltransferase prefers the C-terminal amino acid to be either serine or methionine
for famesylation, while leucine is the residue preferred by GGTase-I (19). Ki-Ras4A, KiRas4B, N-Ras, and RhoB proteins can be either famesylated or geranylgeranylated,
whereas H-Ras proteins are singly famesylated and RhoA proteins are singly
geranylgeranylated (47, 60, 65, 67).
FTase is a heterodimer consisting of a 379-residue a-subunit (44-kD) and 437residue zinc-containing P-subunit (48-kD) (20, 48, 49, 66). Both subunits are organized
as a-helical secondary structures (Fig. 3). The a-subunit is composed of seven pairs of
antiparallel a-helices folded into a crescent shaped structure. The P-subunit forms an
unusual two layer a-helical barrel. The a-subunit is a right-handed superhelix based on
seven copies o f a helix-tum-helix repeat. The a-subunit of the human famesyltransferase
can be phosphorylated by type I TGF-P receptor, and the phosphorylation has been
suggested to serve a regulatory purpose. The P-subunit is a a-helical barrel open at one
end and plugged at the other by a turn in the chain at residues 398-402 near the C-
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terminus. The active site containing Zn is located on the inside of the barrel near its upper
end, where it is coordinated by the side chains of Asp297|3, Cys299p, and His362(3. The
other notable feature o f the barrel is its hydrophobic interior surface: the hydrophobic
character o f the active site fits well with the hydrophobic nature of both famesyl
diphosphate and peptides such as CVIM.
Sequence differences between the rat and human FTase are on the surface of the
enzyme away from the active-site Zn and in the interior of the barrel. This fact, together
with the observation that the rat and human enzymes are closely related with 93%
identity over 379 residues for the a-subunits and 97% identity over 437 residues for the
p-subunits, suggests that the structure of the rat enzyme will be useful for dmg design
efforts.
The a-subunit contacts the P-subunit barrel around half its circumference at the upper
open end o f the barrel (66). This arrangement places several residues of the a-subunit
near the active-site Zn. In particular, the side chains of Lysl64a and His201a contribute
to the formation o f two anion binding sites 6.7A and 7.5 A from the Zn. His248P,
Lys294p, Lys353p, Lys356P, and Arg29ip also contribute to the formation o f the two
binding sites. The proximity of these sites to the active-site Zn as well as their highly
charged character suggest that they represent part of the binding site for the diphosphate
moiety of the substrate famesyl diphosphate. The involvement of residues from both
subunits is consistent with the observation that neither subunit alone is capable of binding
FPP. Thus, both subunits would appear to have a role in binding and orienting the leaving
group o f FPP appropriately for catalysis.
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The FTase reaction can be summarized as (22, 23):
FTase
Protein-CAAX + FPP ------^------ ► Protein-F + PPi
4 -------------

FARNESYLTRANSFERASE INHIBITORS AND CURRENT MODELS OF FTI
MECHANISMS
Three major groups of famesyltransferase inhibitors (FTIs) have been developed (27,
73). The first group is molecules derived via peptidomimetic approches, CAAX
peptidomimetics, such as FTase inhibitor II (Calbiochem) and FTI 277 (Calbiochem).
These compounds inhibit the isolated enzyme at nanomolar concentrations, but none of
them have been developed further as clinically usable anticancer drugs. The second group
is heterocyclic FTIs (R115777, SCH66336) that compete for the CAAX peptide binding
site of FTase, not only inhibiting the isolated FTase at nanomolar concentrations, but also
have demonstrated cytotoxic activity in vitro and in vivo in tumor cell lines with and
without ras gene mutations (10). The third group is the FPP competitive compounds,
such as FPT inhibitor II (CalBiochem) and FPT inhibitor III (Calbiochem), which inhibit
the isolated enzyme FTase at nanomolar concentration and inhibit the growth o f tumors
produced by H-Ras transformed NIH/3T3 cells.
Ras plays a crucial role in cellular signal transduction pathways. The first and most
critical post-translational modification of Ras is famesylation catalyzed by the FTase.
Consequently, inhibitors of FTase have been proposed as potential agents for treating
cancers in which Ras plays a pivotal role (27, 40, 70, 71).
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FIG. 2. Prenylation of cellular proteins. Some proteins such as H-Ras and Lamin B are
modified with the 15-carbon famesyl group, some such as RhoA contain the 20-carbon
geranylgeranyl group, and some such as Rab proteins contain two geranylgeranyl groups.
In all cases, the prenyl groups are at the C-terminus of the protein, and the a-carboxyl
group is often methylated.
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FIG. 3. Structure of famesyltransferase. The X-ray diffraction structure of the FTase
was obtained from the Brookhaven National Library Protein Data Bank. The a-subunit is
composed o f seven pairs of antiparallel a-helices folded into a crescent shaped structure
(Top); the P-subunit forms an unusual two layer a-helical barrel (Bottom)
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Although FTIs were originally developed as a Ras-targeted therapy, it currently
appears that inhibition of Ras famesylation cannot account for all of the actions of the
compounds (27, 41, 42, 43). First, FTIs do not require the presence o f the activated,
mutant Ras protein to produce anti-tumor effects. In other words, the susceptibility of
human tumor cell lines to FTIs is not correlated with Ras mutation status. Secondly, the
Ki-ras4B isoform, the predominant isoform mutated in human cancers, can undergo
geranylgeranylation catalyzed by GGT-I when cells are treated with FTIs (67, 76). Thus,
tumors bearing the mutant Ki-ras4B isoform should be resistant to FTIs; however, some
tumors bearing Ki-ras4B mutations are clearly responsive to FTI treatments. Thirdly, the
relative lack o f cytostatic effects of FTIs on normal cells is curious, because Ras is
required for the proliferation of normal cells. Furthermore, the kinetics of phenotypic
reversion induced by FTI treatment are in many cases simply too rapid to be explained by
loss of Ras function through inhibition o f its famesylation. The reversion process occurs
largely within 24 hours of cell treatment. FTIs only inhibit the production o f newly
synthesized Ras. The Ras protein is quite stable with a half-life of ~24 hours. Thus by the
time reversion is complete, steady-state levels of famesylated Ras are only reduced by
approximately 50%. Finally, even though in vivo tumors seem to regress completely,
cessation of FTI treatment leads to a rapid return of tumors. Tumor persistence would
require continuous long-term FTI treatment that could increase the likelihood of side
effects and drug resistance. Prendergast and his research team in the Wistar Institute
suggested that cell growth inhibition by famesyltransferase inhibitors is mediated by gain
of geranylgeranylated RhoB (41, 42, 43, 56, 57).
RhoB has been implicated as an FTI target for several reasons (15): 1) RhoB is a
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substrate for FTase, and FTIs inhibits its famesylation resulting in decreased RhoB-F and
increased RhoB-GG. Geranylgeranylated forms of RhoB (RhoB-GG) accumulate in
drug-treated cells because of the action of geranylgeranyl transferase-I which is
unaffected by FTI; 2) The short half-life of RhoB coincides better than that of Ras with
regard to the kinetics of the reversal of transformation of FTI; 3) The cell cycle kinase
inhibitor p21 /WAF1/CIP1 is induced in cells and cell growth is inhibited when they are
treated with FTIs; 4) The loss of RhoB-F and the gain of RhoB-GG associated with
stress-fiber formation is compatible with anchorage-dependent growth, but not with
anchorage-independent growth. For example, if Ras-transformed cells are cultured in
suspension, where cell-cell but not cell-substratum attachment is possible, then FTIs
induce massive apoptosis instead of reversion. Taken together, Chen’s results (15)
support the conclusion that alteration of RhoB prenylation is both necessary and
sufficient to the FTI mechanism in malignant cells. Both RhoB-F and RhoB-GG induce
apoptosis, inhibit oncogenic signaling, and suppress transformation in vitro and in vivo
(15).
The Rho GTPases are essential for Ras-induced oncogenic transformation (7, 52,
62), and activated Rho acts synergistically with activated Raf in cell transformation. Raf,
with activated serine/threonine kinase activity, sends positive signals down a kinase
cascade (the mitogen-activated protein kinase pathway) and prompts cells to move
through the G1 phase o f the cell cycle towards S phase of cell cycle. Excessive signaling
from Ras/Raf induces p21/WAFl/CIPl and blocks entry into S phase. Rho A overcomes
the cell-cycle block by suppressing expression of p21 /WAF1/CIP1 (52, 62) (Fig. 4).
Although some evidence showed the involvement of RhoB in the anti-tumor activity
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o f FTIs (15, 42), direct evidence implicating RhoB in the mechanism of action of FTIs in
human tumors is lacking. The roles of RhoB, RhoA, and p21/WAFl/CIPl in cellular
mechanism of FTI anticancer activity have not been determined.

ARGLABIN-DIETHYLAMINOHYDROCHLORIDE
The guaianolide arglabin, a sesquiterpene lactone extracted from Artemisia
myriantha, is used in Chinese medicine for the treatment of menorrhagia and
inflammatory diseases (13, 32, 35, 50). Arglabin is a registered anticancer compound in
the Republic of Kazakstan (1 ,3 ,9 , 63). Over 200 patients with a variety of cancers have
been treated with this compound and generated very promising results and few side
effects. The water soluble dimethylaminohydrochloride derivative of arglabin (arglabinDMA) was used in current anti-tumor treatments and in this study. The formula weight of
arglabin-DMA is 327.85 daltons and the structure of arglabin-DMA is shown in Figure 5.
According to previous research on sesquiterpene lactones (1, 3, 63), arglabin is derived
from trans-famesyl diphosphate by cyclization, rearrangements, and oxidation.
Shaikenov’s studies showed that arglabin-DMA inhibits the incorporation of
famesylpyrophosphate into H-Ras protein by famesyltransferase with the 50% inhibition
concentration (IC50) of 25 pM (63, 64). The phosphorylated form of arglabin-DMA
competitively inhibits the binding of famesylpyrophosphate to famesyltransferases
according to their in vitro kinetic studies (63, 64). Their in vitro studies suggested that
arglabin-DMA inhibited post-translational modification of Ras protein in cells. ArglabinDMA inhibits anchorage-dependent proliferation of neuroblastoma (NB) cells with IC50
o f 10 pg/ml (30.5 pM) and inhibits anchorage-independent growth o f NB and Kirsten
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FIG. 4. Schematic diagram of Ras, RhoA, and p21/WAFl/CIPl proteins in relation to
the cell cycle (52, 62).
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FIG. 5. Structure of arglabin-dimethylamino (arglabin-DMA).
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MSV transformed normal kidney (KNRK) cells with the same IC50 (64). Soft-agar
colony formation assay o f H-Ras transformed cells showed an IC50 of 2 (ig/ml (6.1 pM).
The focus of Shaikenov’s research was to determine whether arglabin-DMA is suitable
for treatment o f ras related malignancies.

PURPOSE OF THIS STUDY
The primary objective o f this study was to better understand the cellular mechanism
o f arglabin-DMA cytotoxic effects on tumor cells. Two general hypotheses were
examined in this study: (1) that arglabin-DMA inhibits protein famesylation in Ras
transformed cells, and (2) that the cytotoxic activity of arglabin-DMA on Ras
transformed cells is primarily derived from famesylation inhibition of Ras protein and/or
Rho protein, and effects on cyclin kinase inhibitor p21/WAFl/CIPl. Three specific aims
were addressed:
Determination o f famesvltransferase inhibitory activity of arglabin-DMA using
famesvltransferase expressed in vitro or produced in transformed cells.
Even though arglabin-DMA is a possible derivative of famesylpyrophosphate (1,3,
63), which is a substrate o f famesyltransferase, and has structural similarity with cellular
polyprenols, direct evidence of arglabin-DMA as a famesyltransferase inhibitor was
lacking. The famesyltransferase assay, using arglabin-DMA and famesyltransferase
expressed in vitro, has not been performed previously. One purpose of this study was
therefore to determine whether in vitro famesyltransferase activity was inhibited by
arglabin-DMA.
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Arglabin-DMA itself may not inhibit famesyltransferase activity. However, a
derivative o f arglabin-DMA such as phosphorylated arglabin-DMA in cells may inhibit
famesyltransferase activity. Shaikenov’s studies showed that arglabin-DMA was
phosphorylated intracellularly and this complex competitively inhibited binding of
famesylpyrophosphate to famesyltransferase, thus inhibiting famesylation o f Ras protein
(63, 64). To further determine whether arglabin-DMA or its derivative inhibit
famesyltransferase activity in cells, investigation of famesyltransferase activity of cell
lysate generated from cells treated with arglabin-DMA was appropriate. The present
study addressed the hypothesis that arglabin-DMA inhibits protein famesylation in Ras
transformed cells.
Determination of the inhibitory effects of arglabin-DMA on famesylation o f Ras
proteins in transformed cells.
Currently, putative FTIs anticancer activity through their effects on oncoproteins is
still speculative. FTIs were originally developed as a Ras-targeted therapy, since the most
frequently detected alterations in oncogenes of human cancers are mutations in the ras
family o f oncogenes, and the most critical post-translational modification o f Ras is
famesylation catalyzed by FTase (27, 45). H-Ras proteins are singly famesylated and KRas protein can be either famesylated or geranylgeranylated. The exact effects of
arglabin-DMA on H-Ras and K-Ras proteins have not been elucidated. The present study
investigated the effects o f arglabin-DMA on H-Ras famesylation and K-Ras prenylation.
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Determination of the effects of arglabin-DMA on Rho protein prenvlation and cvclin
kinase inhibitor p21/WAFl/CIPl production in transformed cells.
RhoB protein can be either famesylated or geranylgeranylated through posttranslational modification. If arglabin-DMA reduces famesylation of RhoB by inhibiting
famesyltransferase activity, more translated RhoB protein is available for
geranylgeranylation, thus more substrate (GGP) and enzymes (GGT-I/GGT-II) are
utilized for RhoB geranylgeranylation. In addition, the half-life of RhoB is about 2 hours,
while that of RhoA is about 24-31 hours, depending on cell type. The rate of RhoB
production is much faster than RhoA. Thus, the total post-translational modification of
RhoB might be kept at the same level. RhoA is singly geranylgeranylated. The
availability of substrates (GGP) and enzymes (GGT-I/GGT-II) for geranylgeranylation
can be limiting due to increased usage by RhoB protein. The reduction of
geranylgeranylated RhoA may decrease the regulatory inhibition of cyclin kinase
inhibitor p21/WAFl/CIPl (Fig. 4). Thus, p21/WAFl/CIPl protein could be expressed
and inhibit transformed cells moving from G1 to S phase of cell cycle.
The effects o f arglabin-DMA on prenylated RhoB protein, geranylgeranylated RhoA
protein, and cyclin kinase inhibitor p21/WAFl/CIPl were investigated. The present
study addressed the hypothesis that the cytotoxic activity of arglabin-DMA on Ras
transformed cells is primarily derived from famesylation inhibition of Ras protein and/or
Rho protein, and effects on cyclin kinase inhibitor p21/W AFl/CIPl.
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MATERIALS AND METHODS

ARGLABIN-DIMETHYLAMINOHYDROCHLORIDE
Arglabin-dimethylaminohydrochoride (arglabin-DMA) was a gift from Dr.
Shaikenov of NuOncology Labs, Inc. Arglabin-DMA is a water soluble form of arglabin
[1(R), 10(S)-epoxy-5(S), 7(S)-guaia-3(4), ll(13)-dien-6, 12-olide], a sesquiterpene ylactone isolated from Artemisia glabella (64). The formula weight of arglabin-DMA is
327.85. The structure o f arglabin-DMA is shown in Figure 4. Lyophilized arglabin-DMA
was dissolved in isotonic saline to make various concentrations of arglabin-DMA used
for the experiments reported here.
Other known FTIs were purchased from Calbiochem. FPP competitive compounds
FPT inhibitor II (Calbiochem 344152) and FPT inhibitor III (Calbiochem 344154) are
phosphonic acids. They are both potent and selective inhibitors of FTase (IC50 = 75 nM).
They also inhibit Ras famesylation in whole cells by 90% at 25 to 250 pM. FTI-277
(Calbiochem 344555) and FTase inhibitor II (Calbiochem 344512) are CAAX
peptidomimetics. They both selectively inhibit FTase with IC50 of 50 nM. FTI-277
inhibits H-Ras processing in whole cells with IC50 of lOOnM. It is also highly effective
and selective in disrupting constitutive H-Ras-specific activation of MAP kinase.
Lyophilized FTIs were dissolved in isotonic saline to make various concentrations for the
following experiments.

MOLECULAR MODELING
The famesyltransferase X-ray diffraction structure consisting of atomic coordinates
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o f the binary complex o f FTase and FPP was taken from the Brookhaven National
Library Protein Data Bank (PDB). The substrate-binding site of the enzyme was prepared
by removing the FPP molecule from the complex. The 3-D molecular structures of all
ligands were drawn based on the 2-D structure diagram with the Insight II software
purchased from Molecular Simulation Inc. (MSI) using a Silicon Graphics computer. The
intermolecular energy o f FTase and various ligands were measured using the Insight II
docking program from MSI (Fig. 5). First, the stable docking models were searched while
covering all possible binding modes and ligand confirmations. The top ten possible
orientations o f a ligand to dock to the active site of FTase were found, and then the
intermolecular energies between the ligand and FTase were calculated. Intermolecular
energies consisted of van der Waals, electrostatic, and hydrogen bond interactions (18,
30, 53). The ligands used for intermolecular energy calculation were FPT inhibitor II,
FPT inhibitor III, FTI-277, FTase inhibitor II, FPP, arglabin-DMA, and phosphorylated
arglabin-DMA.

CULTURE OF H-RAS TRANSFORMED NIH-3T3 CELLS (RAS/3T3 CELLS)
The Ras/3T3 cell line is a gift from Dr. Shaikenov of NuOncology Labs Inc. The
control NIH/3T3 cell line (CRL-1658) was purchased from the American Type Culture
Collection (ATCC) as a continuous cell line established from a NIH Swiss mouse
embryo. Both cell lines were propagated in Dulbecco’s Modified Eagle’s Medium
(DMEM) containing 10% fetal bovine serum (FBS) and 4 mM of L-glutamine at 37 + 1
°C in a CO2 incubator containing 5% CO2 and 95% air.
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FIG. 6. Affinity docking. The intermolecular energy between famesyl pyrophosphate
(middle) and famesyltransferase (peripheral) was calculated using an affininty docking
program (Insight II from Molecular Simulations, Inc.). One frame of the docking process
(interaction o f FPP and active site of FTase) was captured in the figure.
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Representative photos were taken using a digital camera (Olympus, DPI 1) attached
to a phase contrast microscope (Olympus, CK40). Seven-day growth curves were
generated for both cell lines. Cells were seeded at the same densities (5000 cells/cm ) on
day 0, and viable cell numbers were counted each day for 7 days using the trypan blue
exclusion method. Cell densities of both cell lines were calculated.
Suspension culture of Ras/3T3 cells was prepared by using poly (2-hydroxyethyl
methacrylate) (poly-Hema or Poly-HEME) surface coated 6-well tissue culture plates
(71). Each well was coated with 0.8 mL o f 1.2% poly-HEME prepared in 95% of ethanol
and allowed to air dry in a Class II laminar flow hood for 16-18 hours. Ras/3T3 cells
were seeded in the coated plates at 20,000 cells per well density. The number of cells was
counted each day for 6 days using the trypan blue exclusion method. Representative
photos were taken using a digital camera attached to a phase contrast microscope.

IN VITRO CYTOTOXICITY ASSESSMENT OF ARGLABIN-DMA
In vitro cytotoxicity assays were performed using the MTT (3-[4,5-dimethylthiazol2-yl]-2,5-diphenyl tetrazolium bromide) based in vitro toxicology assay kit from Sigma
(Cat# TOX-1). Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring,
yielding purple formazan crystals that are dissolved in acidified isopropanol. The
resulting purple solution is spectrophotometrically measured. An increase or decrease in
cell number results in a concomitant change in the amount of formazan formed,
indicating the degree o f cytotoxicity caused by the test material.
Ras/3T3 cells were seeded at 5000 cells per cm2 in 96-well cell culture plates. After
cells had grown to the mid-log phase, the cell culture media was replaced by various
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concentrations of arglabin-DMA (0, 0.1, 1, 10, 25, 50, andlOO pM) made with complete
cell culture media containing 10% FBS and 4 mM of L-glutamine. For controls, cell
culture media containing 10% FBS and 4 mM of L-glutamine without arglabin-DMA
was introduced to cells. The cells were incubated in a 37°C incubator containing 5%
C(V95% air for 72 hours. A minimum of three replicates was used for each test group
and control. After incubation, the media in each well was replaced by RPMI-1640
without phenol red (150 (ll/well) and MTT solution (15 (ll/well). The 96 well plates were
incubated in a 37°C incubator containing 5% CC>2/95% air for 2 hours. Solubilization
solution (150 pl/well) was added into each well after incubation to dissolve any formazan
crystals formed in viable cells. The absorbency of the resulting solution was measured at
a wavelength o f 570 nm on a plate reader. The background absorbency was measured at a
wavelength of 690 nm on a plate reader. The absorbency of viable cells was calculated by
subtracting background absorbency from the absorbency of the resulting solution. The
results were plotted on Excel worksheets and expressed as absorbency o f the resulting
solution generated from viable cells for each test group and control, or percentages of
viable cells compared to the control. An increase or decrease in cell number resulted in a
concomitant change in the amount of formazan formed, indicating the degree of
cytotoxicity caused by the test material.

FARNESYLTRANSFERASE EXPRESSION AND PURIFICATION
Plasmid DNAs of human famesyltransferase a and (3 subunits (gifts from Dr.
Tomanoi of the University of California in Los Angeles) were used to express human
FTase (Fig. 7 and Fig. 8). The construction of plasmid pMALc2-hFTa contained the
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ampicillin resistance sequence and malE, which encodes maltose-binding protein (MBP).
The plasmid pGEXhFTP construct confered ampicillin resistance sequence and carried
the glutathione S-transferase (GST) gene sequence. Both plasmid DNAs contained the
same promoters for FTase and for induction by isopropyl-beta-D-thiogalactopyranoside
(IPTG).
Plasmid DNAs for a and P subunits of FTase were co-transformed into DH5a
competent Escherichia coli (E.coli) cells by electroporation at 2.5 kV for 5 milliseconds.
These E.coli cells were propagated and selected with a high concentration of ampicillin
(200 |lg/mL). FTa and FTP gene transcription were induced with 1 mM IPTG at 37°C
overnight. The cell pellets were resuspended in sonication buffer (lxPBS/lmM
EDTA/lmM EGTA/ 0.1% Lubrol/ O.lmM DTT) containing protease inhibitor cocktail
(Sigma, P8849) and sonicated on ice. After centrifugation, the supernatants were purified
with glutathione beads by mixing on a rocker at 4°C for 2 hours. The protein was eluted
with elution buffer containing glutathione and concentrated using centrifugal filters
(Amicon, Centricon YM-100, MWCO 100 kilodalton). Protein concentrations were
determined using the bicinchoninic acid (BCA) assay. The relative protein size was
confirmed with electrophoresis on SDS-polyacrylamide gel stained with coomassie blue.
The enzyme activity o f expressed FTase was determined by the subsequent in vitro FTase
assay.
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FIG. 7. Plasmid map o f pMAL. The construction o f plasmid pMALc2-hFTa contained
the ampicillin resistance sequence and malE gene, which encodes maltose-binding
protein (MBP).
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FIG. 8. Plasmid map o f pGEX. The plasmid pGEXhFTP construct contained
ampicillin resistance sequence and the glutathione S-transferase (GST) gene sequence.
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IN VITRO FTASE ASSAY USING FTASE EXPRESSED IN AN E.COLI
EXPRESSION SYSTEM
FTase can transfer the famesyl group of famesylpyrophosphate (FPP) to protein
substrates (such as lamin B or Ras protein) to generate famesylated protein and
pyrophosphate. The in vitro FTase assay quantitates the amount of radio-labeled
famesylated protein using radio-labeled FPP as a substrate (34, 74). The FTase activity
was determined by measuring the incorporation of the 3H-famesyl group of 3H-FPP to the
substrate peptide. The usage of radioactive materials and the experimental procedures
were approved by the Radiation Safety Committee (RSC) of Old Dominion University
(Norfolk, VA).
The Famesyltransferase Scintillation Proximity Assay (SPA) Kit was purchased from
Amersham Life Science (TRKO 7010). Scintillation proximity assay uses
fluoromicrospheres (yttrium silicate beads) coated with streptavidin (12, 34,46). Protein
substrates were labeled with biotin. Famesylpyrophosphate was labeled with tritium (3H)
that emits low energy radiation. During the FTase assay reaction, radioactively labeled
famesylated-biotinylated-protein was generated relative to total famesyltransferase
activity. When this product bound to the beads and, by its proximity, the emitted shortrange electrons of the isotope excited the fluorophor in the bead. The light emitted was
measured using a standard liquid scintillation counter. The enzymatic reaction was started
by adding 20 pi of purified FTase (0.1 pg/pl) into 80 pi of assay buffer consisting of
[3H]-FPP (120 nM), zinc chloride (100 pM), and biotin lamin-B peptide (0.5 pM). The
tubes containing the combined reaction solutions were incubated at 37°C water bath for
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60 minutes. The assay was stopped by the addition of STOP/bead reagent into the
reaction. The resulting solution was counted using a liquid scintillation counter.
A standard curve of FTase activity was generated using increasing amounts of cell
protein (0.4-4 pg) produced from the FTase expression and purification procedures (Fig
9). Reactions without cell protein and reactions without the addition o f arglabin-DMA
were used as negative controls. Reactions using a known FTI, FPT inhibitor II
(Calbiochem 344152) or FTase Inhibitor II (Calbiochem 344512) were used as positive
controls. Various concentrations of arglabin-DMA were tested in FTase assays. The
FTase enzymatic activity was expressed as the amount of radiolabeled famesylated
protein per minute o f reaction (pCi/min). The 50% inhibition concentration (IC50) of
known FTIs and arglabin-DMA were determined. Various concentrations of radiolabeled FPP were used to determine the velocity of enzyme reaction (pmol/min).
Lineweaver-Burk plots o f known FTIs and arglabin-DMA were generated to show the
type of inhibition of famesyltransferase.
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FIG. 9. Standard curve of FTase assay. Various amount of expressed and purified
FTase (0.4 pg - 4 pg) was used for FTase standard curve generation. Generation of 3Hfamesylated-biotin-lamin B peptide was measured by liquid scintillation counter.
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CELL LYSATE PREPARATION
An equal number o f Ras/3T3 cells was seeded in T25 flasks. After cells had grown to
the mid-log phase, various concentrations of arglabin-DMA (0.1, 1, 10, 50, and 100 pM)
were introduced into cell culture media. Once the cells had been treated for 2 hours, 24
hours, or 72 hours, the culture media were removed. Cells were washed with lx
phosphate buffered saline (PBS) and removed from tissue culture flasks using lysis buffer
containing sodium chloride (150 mM), magnesium chloride (5 mM), DTT (ImM),
sodium phosphate (1 mM), triton X-100 (1%), sodium dodecylsulfate (0.05%), HEPES
(50 mM), phenylmethylsulfonyl fluoride (1 mM), sodium vanadate (1 mM), aprotinin (10
pg/mL), and leupeptin (10 pg/mL) (37, 38, 39, 45). Cell suspensions in lysis buffer were
sonicated at 10 watts for a total of 60 seconds. After sonication, cell lysates were
centrifuged at 10,000 relative centrifugal force (ref) for 10 minutes. The supernatants
were transferred to new centrifuge tubes and used for experiments. Protein concentrations
of cell lysates were quantificated using BCA assays. Samples with the equal amounts of
cellular protein were utilized.
The negative control was the cell lysate generated from cells without arglabin-DMA
treatment. The positive control was the cell lysate obtained from cells treated with known
famesyltransferase inhibitor.

PROTEIN QUANTIFICATION
The BCA protein assay™ detects and quantitates total protein in samples by using
reagents containing bicinchoninic acid (BCA). The purple-colored reaction product of
this assay was formed by the chelation of two molecules of BCA with one cuprous ion,
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which generated from reduction of Cu+2 to Cu+1 by protein. Bovine serum albumin (BSA)
ranging from 25 pg/mL to 750 pg/mL was used for standard curve generation. Linearity
exists over the protein concentration range of 25 pg/mL to 750 pg/mL (R =0.9971, Fig.
10). The BCA protein assay was started by addition of 200 pi of working reagent which
contained BCA and cuprous cation (Cu+2) to 25 pi of testing solution (such as cell lysate)
in a 96-well assay plate. The plate was incubated at 37°C for 30 minutes, and the optical
densities of the standard and test samples were measured at absorbency of 570 nm in a
plate reader. The protein concentrations of the testing samples were calculated by
comparing the optical density at 570 nm with the standard curve generated for each
assay. A minimum o f three replicates of each testing sample was used for every protein
assay.

FTASE ASSAY USING FTASE PRODUCED IN H-RAS TRANSFORMED
NIH/3T3 CELLS
The endogenous famesyltransferase activity was tested by an in vitro FTase assay.
This in vitro FTase Assay uses cell lysate as a source of FTase (47, 57, 68, 69). The cell
lysates were generated from Ras/3T3 cells incubated with various concentrations of
arglabin-DMA for 2 hours, 1 day, or 2 days. Tritiated famesylpyrophosphate and Ras
protein were used as the substrates. Tritiated famesylated Ras protein was generated in
proportion to the FTase activity of the cell lysate.
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FIG. 10. Standard curve for BCA Assay. Bovine serum albumin (BSA) ranging from
25 (ig/mL to 750 |4g/mL was used for standard curve generation. The absorbency of BSA
was measured at 570 nm in a plate reader.
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The in vitro FTase assay was initiated by adding 5 (j.1 of cell lysate (15-20 jig protein)
into 45 pi of assay buffer. The assay buffer contained H-Ras protein (100 nM), [3H]FPP
(100 nM, 0.1 pCi), MgCl2 (5 mM), dTT (5 mM), and HEPES (50 mM), and the pH was
adjusted to 7.5 with IN HC1 (47). The reaction was maintained at 37°C for 1 hour and
stopped by adding 1M o f ice-cold hydrochloride (HC1) prepared with ethanol. The
resulting solution was filtered through GF/C filter paper and rinsed by 1 ml of ice-cold
ethanol. The filter paper was dried in air and transferred into scintillation fluid. The
radioactivity was measured by liquid scintillation counter.
Reactions without cell lysate were used as blank negative controls. Reactions using
cell lysate generated from cells without arglabin-DMA treatment, and reactions using
famesyltransferases expressed and purified through prokaryotic system were used as the
other negative controls. Reactions using a known FTI were the positive controls. The
nonspecific activity o f the blank negative control was subtracted from the total
radioactivity of each sample. The specific activity of each sample was calculated by
dividing the radioactivity (counts per minute) by the amount o f protein. The percentage
o f famesyltransferase inhibition of arglabin-DMA in cells was calculated by comparing
the specific activity of each sample to the cell lysate negative control (without arglabinDMA treatment). Three replicates were used for each test and control group. Doseresponse curves for arglabin-DMA were generated.

GEL ELECTROPHORESIS
SDS-polyacrylamide gels (12% or 4-15%) were purchased from Bio-Rad. Precision
pre-stained protein standards ranging from 10 to 250 kD (BioRad, 161- 0373) were used
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to assess the relative protein size and transfer efficiency. Equal amounts of sample buffer
(BioRad, 161-0737) containing beta-mercaptoethinal and protein samples were mixed,
then denatured in boiling water for 5 minutes and stored in wet ice until they were used.
Thirty microliter samples were loaded into each well, and 200 volts of electricity was
used to separate various sizes of proteins in samples. After 1 hour o f electrophresis in lx
Tris-Glycine-SDS (TGS) running buffer (BioRad, 161-0772), the gel was ready for
Coomassie blue staining or protein transfer.

COOMASSIE BLUE STAINING
The SDS-polyacrylamide gel was fixed in solution containing 50% methanol and
10% acetic acid for 30 minutes. After removing fixing solution, the gel was stained with
Coomassie blue stain (BioRad, R-250) and agitated at room temperature for 3 hours.
Approximately 1 (ig of protein per band was needed for detection using Coomassie blue
R-250 staining. The gel was destained with solution containing 5% methanol and 7%
acetic acid overnight on an orbital shaker with slow agitation. A photo of the gel was
taken after destaining process and used for documentation and analysis.

PROTEIN TRANSFER
SDS-polyacrylamide gels from electrophoresis were submerged in lx transfer buffer
containing 20% methanol and lx Tris-Glycine buffer (BioRad, 161-0771) for 15 minutes.
The proteins separated through electrophoresis were transferred to polyvinylidene
difluoride (PVDF) membrane in lx transfer buffer at 350 mA for 1 hour using Mini
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Trans-Blot Cell (Bio-Rad, 170-3930). The transfer efficiency was assessed by examining
the prestained protein standard.

IMMUNOPRECIPITATION
Immunoprecipitation before electrophoresis was used to increase the sensitivity of
Western blot (65, 67). Specific primary antibody (1 pg) was added to 1 mL of cell lysates
according to various manufacturer instructions. After incubating the cell lysate at 4°C for
2-4 hours, the antigen-antibody complexes were generated. ProteinG agarose beads (20
pL) were introduced into cell lysate containing antigen-antibody (Ag-Ab) complexes.
The immunoprecipitation were performed on a rocker at 4°C overnight. Antigen-antibody
complexes attached to agarose beads were separated from cell lysates by centrifugation at
1,000 g for 5 minutes. The precipitates were washed with 1 mL of phosphate buffered
saline (lx PBS) 3-4 times. The final precipitates were resuspended in sample buffer
(BioRad, 161-0737), denatured in boiling water for 5 minutes, and loaded into SDSpolyacrylamide gel for electrophoresis. Antibodies used for immunoprecipitation were
listed in Table 1.

WESTERN BLOT
Following the protein transfer, non-specific protein binding sites were blocked by
agitation PVDF membrane in blocking reagents containing 3% casein and 0.15% Tween20 for 2 hours. The membrane was then incubated with a primary antibody specific to the
antigen o f interest for 2 hours with slow agitation at room temperature. After washing
away unbounded antibody, the blot was incubated with a secondary antibody linked to
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horseradish peroxidase (HRP). Following washing unbounded secondary antibody, the
blot was incubated in the Opt:i-4CN substrate for up to 30 minutes, or until the desired
sensitivity was attained. The Opti-4CN detection system (Bio-Rad, 170-8235) uses
colorimetric horseradish peroxidase substrate, 4-chloro-l-naphthol (4CN), which can
generate the detection sensitivity of 100 pg. The primary and secondary antibodies used
in this study are listed in Table 1.

SMALL GTPASE-PULL DOWN ASSAY
The EZ-Detect™ Ras Activation Kit (Pierce, 89855) and EZ-Dectect™ Rho
Activation Kit (Pierce, 89854) were purchased from PIERCE. This assay quantitates the
active Ras protein (or RhoA protein) by isolating them via their specific downstream
effector Raf protein (or Rhotekin for RhoA protein). The Ras-binding domain (RBD) of
Raf protein was expressed as a Glutathione-fusion protein (GST), which was used to pull
down the active or GTP-bound Ras protein. The Rho-binding domain (RBD) of Rhotekin
was expressed as GST protein as well, which was used to precipitate cellular GTP-bound
RhoA protein. After immobilized bait protein (GST-RBD) was incubated with cell
lysates at 4°C for 1 hour in the presence of a SwellGel Immobilized Glutathione Disc,
GST-RBD of Rafl or GST-RBD of Rhotekin pulled down active Ras protein or active
RhoA protein. The SwellGel Immobilized Glutathione Disc was washed 3 times with 400
(iL of 1xLysis/Binding/Wash buffer. The “interactors” were selectively eluted with
sample buffer by boiling the samples at 95-100°C for 5 minutes. Samples were collected
by centrifugation at 7,200 g for 2 minutes and introduced into SDS-polyacrylamide gel to
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TABLE 1. List of antibodies used for immunoprecipitation (IP) and Western blot (WB)
Antigen

Antibody for IP

Primary Antibody for W B

Secondary Antibody for
WB

Rabbit anti-FTase
Goat anti-Rabbit-IgG-HRP
(3 4 1285a)
Rabbit anti-Rat-IgG-FIRP
H-Ras
M ouse anti-Ras IgG (89855b)
Rat anti-v-H-Ras (OPcl )
Goat anti-Mouse-IgG-HRP
K-Ras
M ouse anti-Ras IgG (89855)
M ouse anti-K-Ras (sc-30)
Goat anti-Mouse-IgG-HRP
RhoA
Rabbit anti-RhoA IgG (scd-179)
M ouse anti-RhoA (sc-418)
M ouse anti-RhoB (scRho B
Goat anti-Mouse-IgG-HRP
Rabbit anti-RhoB Ig G (sc-180)
8048)
M ouse anti-p21W AFl
Goat anti-Mouse-IgG-HRP
P21WAF1
Rabbit anti-p21 IgG (abe-7960)
__________(OP76)__________
341285: Antibody from Calbiochem -Novabiochem Corporation (San D iego, CA). 89855: Antibody
from PIERCE Biotechnology, Inc. (Rockford, IL).COP: Antibodies from O ncogene Research Products (San
D iego, C A ).d sc: Antibodies from Santa Cruz Biotechnology, Inc. (Santa Cruz, C A ).e ab: Antibodies from
Abeam Limited (Cambridgeshire, UK).
FTase

N /A
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separate different sizes of proteins. The pulled-down active Ras and Rho protein were
detected by a Western blot.

DENSITOMETRY ANALYSES
The intensity of the bands from Western blot was determined by densitometry using
the Quantity One system (4.6) from Bio-Rad according to the manufacturer instruction.
Briefly, the images of blots were scanned and stored in a computer. The bands of interest
were selected using Quantity One program. Values of maximum intensity (INT),
minimum intensity (INT), mean (INT), standard deviation, volume area (mm2), density
(INT/mm ), and background intensity (INT) were assessed and calculated using Quantity
One program.

STATISTICAL ANALYSES
Each data point consists of at least 3 replicates in all statistical analyses. Linear
regression analyses were used to derive standard curves. An analysis of variance
(ANOVA) was used to determine the significant differences among all experimental
groups. Two-sample t-tests were performed to compare the differences between any 2
specific groups. A confidence level of 95% was considered to be statistically significant.
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RESULTS

IN VITRO CYTOTOXICITY OF ARGLABIN-DMA
Characterization of H-Ras Transformed NIH-3T3 Cells and NIH/3T3 Cells
Both Ras/3T3 cells and NIH/3T3 cells were propagated in Dulbecco’s Modified
Eagle’s Medium (DMEM) containing 10% fetal bovine serum and 4 mM of L-glutamine
at 37 °C in a C 0 2 incubator containing 5% C 0 2/95% air. Photos of representative cell
morphologies of NIH/3T3 cells and Ras/3T3 cells were taken using a digital camera
attached to the microscope (Fig. 11). NIH/3T3 cells showed monolayer morphology
when cells reached confluence (Fig. 11 A). Ras/3T3 cells showed cluster formation and
loss o f “contact inhibition” (piled up) in culture (Fig. 1IB). Normal diploid mammalian
cells, such as NIH/3T3 cells, have a phenomenon called density-dependent inhibition of
growth or “contact inhibition”, which means the cell-cell contact stops cell replication
(61). The transformed cells, such as Ras/3T3, not only have decreased density-dependent
inhibition of growth, but also loss of anchorage dependence (Fig. 12A). Ras/3T3 cells
had grown in suspension culture where the plates were coated with poly-HEME (Fig.
12B).
Viable cell numbers were counted using the Trypan Blue exclusion method for a
continuous seven days after seeding 5,000 cells/cm on day 0. The seven-day growth
curves showed that the number of NIH/3T3 cells plateau at 60,080 cells/cm (Fig. 13),
while the number of Ras/3T3 cells plateau at 308,200 cells/cm2. Population doubling
time (PDT) from day 1 to day 4 was 23.51 hours for NIH/3T3 cells and 17.45 hours for
Ras/3T3 cells. The number of Ras/3T3 cells increased significantly for 5 days until the
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nutrients in culture media were exhausted. The number of NIH/3T3 cells increased for 4
days until cells reached confluence.
In Vitro Cytotoxicity Assessment o f Arglabin-DMA
Arglabin-DMA at concentrations of 0.1 pM, 1 pM, 10 pM, 50 |iiM, and 100 fiM
were prepared with DMEM containing 10% FBS and 4 mM of L-glutamine. Equal
numbers of Ras/3T3 cells and NIH/3T3 cells were seeded in 96-well plates. After 48
hours o f incubation at 37 °C in a CO2 incubator containing 5% of CC>2/95% air, the
culture media was replaced by culture media containing various concentrations of
arglabin-DMA. Cells incubated in medium alone were used as negative controls. Cells
incubated with 5% sodium azide were used as a positive control. After 72 hours of
incubation with arglabin-DMA, in vitro cytotoxicity assays were performed using the
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) based in vitro
toxicology assay kit from Sigma (TOX-1). An increase or decrease in cell number results
in a concomitant change in the amount of formazan formed, indicating the degree of
cytotoxicity caused by the test material. Absorbencies of viable cells were measured
using a plate reader (Labsystems, MultiSkan Ascent).
The absorbency of the Ras/3T3 cell control (OD =1.014) was more than twice that
o f the NIH/3T3 cell control (OD = 0.4457) after 72 hours of incubation. Dose-response
curves for arglabin-DMA were generated for both cell lines (Fig. 14). Concentrations of
arglabin-DMA (pM) were plotted in logarithmic scale. A trend line was generated from
the plot using percentage of growth inhibition (compared to the positive control cells
without arglabin-DMA treatment) versus logarithmic scale of arglabin-DMA
concentrations (pM)) (Fig. 15). Regression analysis showed 96% correlation between
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concentration of arglabin-DMA and percentage of growth inhibition. The 50% inhibition
concentration (IC50) of arglabin-DMA for Ras/3T3 cells estimated from the plot was
10.34 pM, and the IC90 was 79.28 pM. The concentration o f arglabin-DMA used to
inhibit half o f Ras/3T3 cell growth was 10.34 pM, while the concentration of arglabinDMA used to inhibit the same number of NIH/3T3 cells was more than 100 pM,
approximately 10-fold greater than the concentration for Ras/3T3 cells.

THE EFFECT OF ARGLABIN-DMA ON FTASE ACTIVITY
Binding Affinity of Arglabin-DMA and FTase
The X-ray diffraction structure of the FTase and FPP complex was taken from the
Brookhaven National Library Protein Data Bank. The 3-D molecular structures of all
ligands were drawn based on the 2-D structure diagram using the Insight II software. The
intermolecular energy of FTase and various ligands were measured using the Insight II
docking program (Appendix A).
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0.1mm

FIG. 11. Confluent Ras/3T3 cells and NIH/3T3 cells in culture. Figure 11A monolayer of NIH/3T3 cells after reaching confluence. Figure 1IB - Ras/3T3 cells
formed clusters and loss o f “contact inhibition” (piled up) in culture. All of the photos
shown here were taken at lOOx magnification.
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FIG. 12. Growth of Ras/3T3 cells in suspension. Figure 12A - Ras/3T3 cells grown in
poly-HEME coated tissue culture plates. Figure 12B - growth curve for Ras/3T3 cells
grown in suspension in poly-HEME coated tissue culture plates. The photo shown here
was taken at lOOx magnification.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

45

350000
o

300000

g

250000

-■— Ras/3T3
■A -

NIH/3T3

200000
150000

100000
50000

0

1

2

3

4

5

6

7

8

day
FIG. 13. Growth curves of Ras/3T3 cells and NIH/3T3 cells. Viable cell numbers were
counted each day for 7 days. The number o f Ras/3T3 cells increased significantly for 5
days until the nutrients in culture media were exhausted. The number o f NIH/3T3 cells
increased for 4 days until cells reached confluence.
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FIG. 14. Dose-response curves ofNIH/3T3 cells and Ras/3T3 cells to arglabin-DMA.
Culture media containing various concentrations of arglabin-DMA (0.1, 1, 10, 50, or 100
pM) were used to incubate with cells for 72 hours. The absorbencies obtained from MTT
assays reflect the viable cell number for both cell lines, indicating the degree of
cytotoxicity caused by the test material. For the Ras/3T3 cell control and NIH/3T3 cell
control (not shown in this figure), the absorbency of viable Ras/3T3 cells (OD = 1.014)
was more than twice as much as the absorbency of viable NIH/3T3 cells (OD = 0.4457).
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FIG. 15. Percentage Ras/3T3 cell growth inhibition by arglabin-DMA. A trend line was
generated from the plot using percentage of growth inhibition (compared to the positive
control cells without arglabin-DMA treatment) versus logarithmic scale of arglabin-DMA
concentrations (pM). The 50% inhibition concentration (IC50) of arglabin-DMA for
Ras/3T3 cells estimated from the plot was 10.34 pM, and the IC90 was 79.28 pM.
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The mean of the intermolecular energy of all ten possible frames and standard
deviation for each pair o f ligand and FTase were calculated and shown in Table 2. The
difference in intermolecular energy was statistically significant between pairs of all seven
ligands (Appendix B) (p < 0.05). The lower the intermolecular energy, the higher the
binding affinity o f ligand and FTase will be (18, 30). The intermolecular energy between
arglabin-DMA and FTase (-46.97 kCal/mol) was significantly higher than the
intermolecular energy between FPP and FTase (-60.8 kCal/mol) (p < 0.05) (Table 2),
which means that arglabin-DMA was not able to compete for the FTase binding site with
FPP. The intermolecular energy between FTase inhibitor II and FTase (-57.57 kCal/mol),
the energy between phorsphorylated arglabin-DMA and FTase, and the energy between
FTI-277 and FTase were not significantly different from the intermolecular energy
between FPP and FTase (p > 0.05). Intermolecular energy between FPT inhibitor II and
FTase and intermolecular energy between FPI inhibitor III and FTase were significantly
lower than the intermolecular energy between FPP and FTase (p < 0.05). These results
suggested that arglabin-DMA itself may not bind to FTase directly and arglabin-DMA
itself is not a potent FTase inhibitor.
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TABLE 2. Intermolecular energy between FTase and various ligands
Ligands
FPT Inhibitor II
FPT Inhibitor III
FTI-277
Phosphorylated Arglabin-DM A
FPP
FTase Inhibitor II
Arglabin-DM A

Intermolecular Energy (kCal/mol)

Stdev

-82.19
-78.90
-65.93
-63.70
-60.80
-57.57
-46.97

12.16
5.37
10.26
4.76
5.56
7.31
4.62
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The Effect o f Arglabin-DMA on Expressed and Purified FTase Activity
Verification o f the Expressed and Purified FTase
Human FTase a and p subunits were expressed in competent E.coli cells, purified
through glutathione affinity chromatography and concentrated by centrifugation using
centrifugal filters with 100 kiilodalton molecular weight cutoff (MWCO). The protein
concentration of the purified FTase was determined by BCA protein assay. The relative
protein size was confirmed by electrophoresis of the purified protein on SDSpolyacrylamide gel stained with Coomassie blue. Coomassie blue staining showed two
separate bands: one band had a relative size of 90 kD the second band with a relative size
of 70 kD when compared to the ladder (Fig. 16). The relative protein size of MBP-FTa
should be 74.1 kD, which included MBP (29.7 kD) and the FT a-subunit (44.4 kD). The
relative size of GST-FT|3 should be 90.2 kD, including GST (42 kD) and the FT 0subunit (48.8 kD).
The enzymatic activity of the expressed and purified FTase was determined by in
vitro FTase assay. The standard curve of FTase activity was generated using increasing
amounts of cellular protein (0.4-4 (0 ,g) (Fig. 9). Generation of H-famesylated-biotinlamin B peptide was measured by liquid scintillation counter (microcurie/min). Linearity
existed over the range o f 0.4 |ig to 4 (ig of purified protein (R = 0.9956, Fig. 9). Two
micrograms of cellular protein was chosen to use for the following in vitro FTase assays.

FTase Assay using expressed and purified FTase
The FTase activity was determined by measuring the incorporation of the 3H-famesyl
group o f 3H-FPP to the substrate peptide, lamin-B. Various concentrations of arglabin-
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DMA (50, 100, 1000, 2000, 4000, and 8000 pM), FPT inhibitor II (1, 10, 50, 100, 1,000,
5,000, and 10,000 nM), or FTase inhibitor II (0.01, 0.05, 0.1, 0.5, 1, 5, and 10 pM) were
tested in FTase assays. The FTase enzymatic activity was expressed as the amount of
radiolabeled famesylated protein per minute of reaction (pCi/min). Dose-response curves
for arglabin-DMA, FPT inhibitor II, and FTase inhibitor II are shown in Figure 17,
Figure 19, and Figure 21. Percentages of FTase inhibition by various compounds were
calculated by comparing the FTase activity to the no-treatment control. Trend lines were
generated from percentage inhibition plots (Fig. 18,-Fig. 20, Fig. 22). The 50% inhibition
concentration (IC50) of known FTIs and arglabin-DMA were estimated from the
equation o f the linear regression.
FPT inhibitor II is a phosphonic acid, an FPP analogue, which competes for the FPP
binding site of FTase. FTase assay showed significant inhibition at nanomolar
concentrations o f FPT inhibitor II (Fig. 17). Linearity exists over FPT inhibitor II
concentrations ranging from 10 nM to 1000 nM (R2 = 0.975, Fig. 18). The IC50 of FPT
inhibitor II calculated from the equation of the linear regression was 119 nM. FTase
inhibitor II is a pepidomimetic inhibitor of FTase, which competes for the protein binding
site of FTase. FTase assays indicated significant inhibition of FTase activity at
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FIG. 16. Coomassie blue staining of expressed and purified FTase. The relative protein
size o f MBP-FTa was 74.1 kD, which included MBP (29.7 kD) and FT a-subunit (44.4
kD). The relative size o f GST-FTJ3 was 90.2 kD that included GST (42 kD) and FT 13subunit (48.8 kD).
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micromolar concentrations o f FTase inhibitor II (Fig. 19). The IC50 of FTase inhibitor II
calculated from the equation of the linear regression of the percentage inhibition plot was
5.09 pM (R = 0.972, Fig. 20). FTase assay using various concentrations of arglabinDMA showed that FTase activity was inhibited by arglabin-DMA at millimolar
concentrations (Fig. 21). Linearity exists over the arglabin-DMA concentration ranging
from 500 |iM to 8000 pM (R2 = 0.9776, Fig. 22). The IC50 for Arglabin-DMA calculated
from the equation o f the linear regression was 2.9 mM.

Lineweaver-Burk Double Reciprocal Plot o f Arglabin-DMA and Known FTIs
The Lineweaver-Burk plot shows 1/v (velocity) versus 1/[S] (substrate
concentration), which gives a straight line with a slope of Km/Vm and a y-intercept of 1/Km. Thus, Vm (maximum velocity) and Km (Michaelis constant) can be obtained from
the plot. The Michaelis constant is an indication of the relative affinity of the enzyme for
the substrate (51, 58). The lower the Michaelis constant, the higher affinity between
substrate and enzyme. Various concentrations of tritium-labeled FPP (2, 4, 8, and 16 pM)
were used to determine the velocity of enzyme reaction (pmol/min). The LineweaverBurk plot o f FPT inhibitor II was generated from FTase assays using various
concentrations o f tritium-labeled FPP and three concentrations of FPT inhibitor II (0 nM,
10 nM, 100 nM) (Fig. 23). The Lineweaver-Burk plot of FTase inhibitor II was generated
from FTase assays using various concentrations of tritium-labeled FPP and three
concentrations of FTase inhibitor II (0 nM, 500 nM, 5,000 nM) (Fig. 24). The
Lineweaver-Burk plot of arglabin-DMA was generated from FTase assay using various
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FIG. 17. Dose response curve of FPT inhibitor II. Various concentrations of FPT
inhibitor II (1, 10, 50, 100, 1,000, 5,000, and 10,000 nM) were used for FTase assay.
FTase activity was reduced significantly when the concentration of FPT inhibitor II was
between 10 nM tol,000 nM.
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FIG. 18. Percentage of inhibition o f FTase activity by FPT inhibitor II. A trend line
was generated from the plot using percentage of inhibition versus logarithmic scale of
FPT inhibitor II concentrations (nM). Linearity exists over FPT inhibitor II concentration
ranging from 10 nM to 1000 nM (R2 = 0.975). IC50 of FPT inhibitor II calculated from
the equation of linear regression was 119 nM.
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FIG. 19. Dose response curve of FTase inhibitor II. Various concentrations of FTase
inhibitor II (0.01, 0.05, 0.1, 0.5, 1, 5, and 10 pM) were used for FTase assay. FTase
activity was reduced significantly when the concentration of FTase inhibitor II was
between 1 pM to 10 pM.
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FIG. 20. Percentage of inhibition of FTase activity by FTase Inhibitor II. A trend line
was generated from the plot using percentage of inhibition versus logarithmic scale of
FTase inhibitor II concentrations (nM) (R2 = 0.972). IC50 of FTase inhibitor II calculated
from the equation of the trend line was 5.09 pM.
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FIG. 21. Dose response curve of arglabin-DMA. Various concentrations of FTase
inhibitor II (50,100,1000,2000,4000, and 8000 pM) were used for FTase assay. FTase
activity was reduced significantly when the concentration of arglabin-DMA was between
1 mM and 8 mM.
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FIG. 22. Percentage o f inhibition of FTase activity by arglabin-DMA. A trend line was
generated from the plot using percentage of inhibition versus logarithmic scale of
arglabin-DMA concentrations (pM). Linearity exists over arglabin-DMA concentration
ranging from 100 pM to 8,000 pM (R2 = 0.976). The IC50 of arglabin-DMA calculated
from the equation of linear regression was 2.9 mM.
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concentrations of tritium-labeled FPP and three concentrations of arglabin-DMA (0 pM,
1 pM, 4 pM) (Fig. 25).
Lineweaver-Burk double reciprocal plots of 1/v versus 1/[S] showed that Vm (0.75
pmol/min) were nearly identical for three different concentrations of FPT inhibitor II
(Fig. 23). Km changed at different FPT inhibitor concentrations. The plot indicates
competitive inhibition of FTase by FPT inhibitor II, which means that FTI inhibitor II
competes with the FPP for binding to the active site of FTase. The Lineweaver-Burk
double reciprocal plot of FTase inhibitor II showed a constant slop (Km/Vm), but both
Km and Vm changed with various concentrations of FTase inhibitor II. These results
indicated that FTase inhibitor II was an uncompetitive inhibitor of FTase (Fig 24), which
means FTase inhibitor II binds to the FPP-FTase complex, not FTase. The LineweaverBurk double reciprocal plot of arglabin-DMA was more like the double reciprocal plot of
FTase inhibitor II with a contant slope (Km/Vm) (Fig. 25). This suggests that arglabinDMA may bind to FPP-FTase complex and inhibits FTase activity at higher
concentrations than FPT inhibitor II and FTase inhibitor II.
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FIG. 23. Lineweaver-Burk double reciprocal plots of FPT inhibitor II. FTase-catalyzed
reaction velocity (1/v) versus substrate concentration (1/[S]) using various concentrations
o f FPT inhibitor II (0 nM, 10 nM, 100 nM). Vm was constant for three different
concentrations o f FPT inhibitor II (0.75 pmol/min). Km was changed at different FPT
inhibitor II concentrations.
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FIG. 24. Lineweaver-Burk double reciprocal plots of FTase inhibitor II. FTasecatalyzed reaction velocity (l/v) versus substrate concentrations (1/[S]) using 0 nM, 500
nM, or 5,000 nM o f FTase inhibitor II. A constant slope (Km/Vm) and various Km and
Vm were found in three different concentrations of FTase inhibitor II.
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FIG. 25. Lineweaver-Burk double reciprocal plots of arglabin-DMA. FTase-catalyzed
reaction velocity (1/v) versus substrate concentration (1/[S]) using various concentrations
of arglabin-DMA (0 pM, 1 pM, 4 pM). The slopes (Km/Vm) of all three concentrations of
arglabin-DMA were constant, but both Km and Vm changed with various concentrations
of arglabin-DMA.
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The Effect of Arglabin-DMA on FTase Produced in Transformed Cells
Farnesyltransferase Production in Arglabin-DMA Treated Ras/3T3 Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of
arglabin-DMA (0, 0.1, 1, 10, 50, and 100 |xM), or 0.25 pM of FTI-277 for 24 hours or 72
hours, since the half-life of FTase in cells is around 24 hours. Cell lysates were generated,
and the concentrations of cellular protein were determined by BCA protein assays. Equal
amounts o f cellular protein were separated in SDS-polyacrylamide gel, and the amounts
of FTase in gels were determined by Western blot using rabbit anti-famesyltransferase
monoclonal antibody. The densities of each band were quantitated using Quantity One
densitometry software from Bio-Rad.
Two band sizes appear on Western blots: the top band (48.8 kDa) represents the FT
P-subunit, and the bottom band (44.4 kDa) represents the FT a-subunit. Western blots for
FTase after 24 hours and 72 hours of incubation with arglabin-DMA or FTI-277 are
shown in figure 26A and figure 27A. There was no significant difference between
densities of bands detected by densitometry (Fig. 26 B and Fig.27B). These results
suggested that neither arglabin-DMA nor FTI-277 affected FTase production in Ras/3T3
cells.
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FIG. 26. Western blot o f FTase after 24-hour incubation with arglabin-DMA or FTI277. Ras/3T3 cells were incubated with complete cell culture media containing 0, 0.1, 1,
10, 50, or 100 pM of arglabin-DMA or 0.25 pM of FTI-277 for 24 hours. FTase in cellular
protein was detected and shown in figure 26A. The total densities of bands for each
concentration group were shown in figure 26B. No significant difference was found
between groups.
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FIG. 27. Western blot of FTase after 72-hour incubation with arglabin-DMA and FTI277. Ras/3T3 cells were incubated with complete cell culture media containing 0, 0.1, 1,
10, 50, or 100 pM of arglabin-DMA, or 0.25 pM of FTI-277 for 72 hours. FTase in
cellular protein was detected and shown in figure 27A. The total densities of bands for
each concentration group were shown in figure 27B. No significant difference was found
between groups.
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FTase Assay using FTase Produced in Ras/3T3 Cells
Equal numbers o f Ras/3T3 cells were incubated with various concentrations of
arglabin-DMA or FTI-277 for 2 hours, 1 day or 2 days. Cell lysates were generated, and
the concentrations o f cellular protein were determined by BCA protein assays. Equal
amounts o f cellular protein were used in the FTase assays. Tritiated
famesylpyrophosphate and Ras protein were used as the substrates. Tritiated famesylated
Ras protein was generated in proportion to the FTase activity of the cell lysate. Reactions
using cell lysates generated from cells without arglabin-DMA treatment were used as the
negative control. Reactions using cell lysates incubated with FTI-277 were the positive
controls.
When low concentrations of arglabin-DMA (10, 50, 100, and 1,000 nM) were used
on Ras/3T3 cells for a short period (2 hours), a significant reduction in the specific
activity o f FTase was found at thelO nM concentration of arglabin (p < 0.05) (Fig. 28).
The reduction plateaued when the concentration o f arglabin-DMA reached 100 nM. The
specific activity difference between 100 nM and 1,000 nM arglabin-DMA groups was not
significant (p > 0.05). Percentage of FTase inhibition was calculated by comparing the
specific activity with the no arglabin-DMA control. The highest inhibition of FTase
activity was 59% when 100 nM arglabin-DMA was used on Ras/3T3 cells for 2 hours
(Fig. 29). These results were derived from 3 separate experiments. The percentage of
inhibition o f FTase activity by 1,000 nM of FTI-277 was 90%. These results suggested
that low concentrations (10-1,000 nM) of arglabin-DMA inhibited FTase activity after 2
hours of incubation with Ras/3T3 cells. However, this inhibition was limited by the
substrate availability in cells that may transform arglabin-DMA to a famesyltransferase
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inhibitor, such as phosphorylated arglabin-DMA.
When higher concentrations of arglabin-DMA (25, 50, 75, and 100 pM) were used
on Ras/3T3 cells for longer times (1 day or 2 days), percentage inhibitions plateaued at
75 pM for both incubation times (Fig. 30 and Fig. 31). After incubation with arglabinDMA for these longer times, the enzyme activity of the newly synthesized FTase was
inhibited by much higher concentrations of arglabin-DMA (50 pM to 100 pM). This may
imply that arglabin-DMA was transformed to an FTase inhibitor inside of cells and this
transformation was not reversible. Another possibility was that some arglabin-DMA or its
derivatives were degenerated inside of cells after longer period o f incubation. Therefore,
after large amount o f newly synthesized FTase appeared in cells, more arglabin-DMA
was needed to inhibit FTase activity.

THE EFFECT OF ARGLABIN-DMA ON RAS PROTEIN IN TRANSFORMED
CELLS
The Effect of Arglabin-DMA on H-Ras Protein in Transformed Cells
Equal numbers o f Ras/3T3 cells were incubated with various concentrations of
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (control) for 24 hours
or 72 hours. Cell lysates were generated, and the concentrations of cellular protein were
determined by BCA protein assays. Equal amounts of cellular protein were separated in
SDS-polyacrylamide gel, transferred to PVDF membrane, and the amounts of H-Ras
protein determined by western blot using rat anti-v-H-Ras monoclonal antibody. The
recombinant H-Ras protein (Sigma, R-9894) was used as a positive control for the
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FIG. 28. Specific activity of FTase after 2-hour incubation with arglabin-DMA. A
significant reduction in specific activity of FTase was found at 10 nM concentration of
arglabin (p < 0.05). The reduction plateaued when the concentration of arglabin reached
100 nM. The specific activity difference between 100 nM and 1,000 nM arglabin-DMA
groups was not significant (p > 0.05).
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FIG. 29. Percentage of FTase inhibition after 2-hour incubation with arglabin-DMA.
Percentage o f FTase inhibition was calculated by comparing the specific activity with the
no arglabin-DMA control. The highest inhibition o f FTase activity was 59% when 100
nM arglabin-DMA was used to incubate Ras/3T3 cells for 2 hours.
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FIG. 30. Percentage o f FTase inhibition after 1-day incubation with arglabin-DMA.
Percentage of inhibitions plateaued after 1-day incubation with 75 pM of arglabin-DMA.
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FIG. 31. Percentage of FTase inhibition after 2-day incubation with arglabin-DMA.
Percentage o f inhibitions plateaued after 2-day incubation with 75 pM of arglabin-DMA.
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western blot. The densities o f each band were quantitated using Quantity One
densitometry software from Bio-Rad.
The prenylated (processed) and non-prenylated (non-processed) Ras proteins were
separated by electrophoresis and detected by Western blot (53, 58). The faster-migrating
immunoreactive bands represented mature, fully processed protein, whereas the slowermigrating form was unprocessed protein (62) (Fig. 32, 33).). The relative molecular
weight of the processed protein estimated from the Precision protein standard (BioRad,
161-0373) was 21 + 1 kD. The Western blots for cells incubated with arglabin-DMA (0,
0.1, 1, 10, 50, 100 pM) or FTI-277 (0.25 pM) for 24 hours or 72 hours are shown in
Figures 32A and 33A, respectively. A trend of increasing densities of the slowermigrating bands was found as the concentration of arglabin-DMA increased from 0 pM
to 100 pM, and the density of the slower-migrating band for the FTI-277 group reached
the highest level (Fig. 32A and Fig. 33A). The ratio of densities of faster-migrating bands
(processed H-Ras protein) to densities of slower-migrating bands (unprocessed H-Ras
protein) was calculated and shown in Figures 32B and 33B. The percentage reduction of
the ratio was calculated by comparing the ratio of densities to the no arglabin-DMA
treatment control. After cells were incubated with 100 pM of arglabin-DMA for 24 hours
or 72 hours, percentages o f reduction of ratio of processed to unprocessed H-Ras protein
were 18.6% and 9.5%, respectively (Fig. 32B and Fig. 33B). When cells were incubated
with FTI-277 for 24 hours or 72 hours, the percentages of ratio reduction were 46% and
26.5%, respectively. These results were derived from 4 separate experiments.
Equal amounts of cellular protein from various treatment groups were utilized in
small GTPase-pull down assays. The complexes of GST-Rafl-RBD and active Ras
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protein were selectively eluted from glutathione discs, separated in SDS-polyacrylamide
gel, transferred to PVDF membrane, and the amounts of H-Ras protein were determined
by western blot using rat anti-v-H-Ras monoclonal antibody. There were multiple bands
detected in the western blots (Fig. 34A-B). When cell lysates incubated with arglabinDMA or FTI-277 for 24 hours were used for the pull-down assay, the bands with the
highest density were found at relative molecular weight of 40 + 2 kD compared to the
protein standard (Fig. 34A). No band with molecular weight of 21 + 1 kD was detected.
This may be due to the Ras protein dimer formation during the pull-down process. The
densities o f bands were reduced significantly on lanes of 50 pM and 100 pM arglabinDMA (Fig. 34A). When cell lysates incubated with arglabin-DMA or FTI-277 for 72
hours were used for the pull-down assay, bands with relative molecular weight of 39 + 1
kD were detected in all tested samples (Fig. 34B). Significant density reductions were
found in lanes o f 1 pM, 10 pM, 50 pM, and 100 pM arglabin-DMA and FTI-277. These
data suggested that arglabin-DMA or FTI-277 inhibited active H-Ras formation in
Ras/3T3 cells.
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FIG. 32. Western Blot of H-Ras after 24-hour incubation with Arglabin-DMA or FTI277. A trend of increasing densities of slower-migrating bands was found as the
concentrations o f arglabin-DMA increased from 0 |iM to 100 gM, and the density o f the
slower-migrating band for FTI-277 group reached its highest level (Fig. 32A). The ratios
of densities o f faster-migrating bands (processed H-Ras protein) to densities of slowermigrating bands (unprocessed H-Ras protein) were calculated and shown in figure 32B.
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FIG. 33. Western Blot of H-Ras after 72-hour incubation with Arglabin-DMA or FTI277. A trend of increasing on densities of slower-migrating bands was found as the
concentrations of arglabin-DMA increased from 0 pM to 100 gM, and the density of the
slower-migrating band for FTI-277 group reached the highest (Fig. 33A). The ratios of
densities o f faster-migrating bands (processed H-Ras protein) to densities of slowermigrating bands (unprocessed H-Ras protein) were calculated and shown in figure 33B.
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FIG. 34. Western blot of H-Ras protein after small GTPase pull-down assays. When
cell lysates incubated with arglabin-DMA or FTI-277 for 24 hours were used for the pull
down assay, the bands with the highest density were found at relative molecular weight
of 40 + 2 kD compared to the protein standard (Fig. 34A). The densities of bands reduced
significantly after 50 pM and 100 pM arglabin-DMA incubation. When cell lysates
incubated with arglabin-DMA or FTI-277 for 72 hours were used for the pull-down
assay, bands with relative molecular weight of 39 + 1 kD were detected in all tested
samples (Fig. 34B). Significant density reductions were found in lanes of 1 pM, 10 pM,
50 pM, and 100 pM arglabin-DMA and FTI-277.
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The Effect of Arglabin-DMA on K-Ras Protein in Transformed Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (positive control) for
24 hours. Cell lysates were generated, and the concentrations of cellular protein were
determined by BCA protein assays. Equal amounts of cellular protein were separated in
SDS-polyacrylamide gel, transferred to PVDF membrane, and the amounts of K-Ras
protein were determined by Western blot using mouse anti-K-Ras monoclonal antibody.
Cell lysates from rat K-Ras transformed kidney (KNRK) cells (Santa Cruz, Inc. SC2214), was used as a positive control for Western blot. The densities of each band in
tested samples were quantitated using Quantity One densitometry software from BioRad.
The KNRK cell lysate control showed two bands, one faster-migrating band
(processed K-Ras protein) and one slower-migrating band (unprocessed K-Ras protein)
(Fig. 35A). The relative molecular weight o f the processed protein estimated from the
Precision protein standard (BioRad, 161-0373) was 21 + 1 kD. Only one band in each
sample was detected in Western blot for Ras/3T3 cell lysates that was incubated with
arglabin-DMA, FTI-277, or no treatment control (Fig. 35A). All tested samples have only
the faster-migrating bands (processed K-Ras protein) when compared to the KNRK cell
lysate control. The densities of each test samples are shown in figure 35B. No significant
difference was found between band densities of all test samples. The data was collected
from two separate experiments. These results suggested that FTase inhibitors have no
effect on K-Ras prenylation, since all K-Ras were post-translational modified by
geranylgeranylation o f GGTasel.
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FIG. 35. Western blot o f K-Ras after 24-hour incubation with arglabin-DMA or FTI277. All tested samples only have the faster-migrating bands (processed K-Ras protein)
when compared to the KNRK cell lysate control (Fig. 35A). No significant differences
were found between band densities of all test samples (Fig. 35B).
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THE EFFECT OF ARGLABIN-DMA ON RHO PROTEIN IN TRANSFORMED
CELLS
The Effect o f Arglabin-DMA on RhoA Protein in Transformed Cells
Equal numbers of Ras/3T3 cells were incubated with various concentrations of
arglabin-DMA (0.1, 1, 10, 50, and 100 gM) or 0.25 gM of FTI-277 (positive control) for
24 hours and 72 hours. Cell lysates were generated, and the concentrations of cellular
proteins were determined by BCA protein assays. Equal amounts of cellular protein were
separated in SDS-polyacrylamide gel, transferred to PVDF membrane, and the amount of
RhoA protein were determined by western blot using mouse anti-RhoA monoclonal
antibody. The Hela cell lysate (Santa Cruz, Inc. SC-2200) from human epithelioid
carcinoma cells was used as a positive control for western blot. The densities of each
band of all tested samples were quantitated using Quantity One densitometry software
from Bio-Rad.
Two bands were detected from Hela cell lysate control: the faster migrating band
(processed RhoA protein) and the slower migrating band (unprocessed RhoA protein)
(Fig. 36A-B and Fig. 37A). The relative molecular weight of the processed protein
estimated from the Precision protein standard (BioRad, 161-0373) was 21 + 1 kD. After
24 horns o f incubation with various concentrations of arglabin-DMA or FTI-277, one
band from each sample was detected in Western blots (FIG. 36A-B). The bands from 10
gM, 50 gM, lOOgM arglabin-DMA, and FTI-277 were the slower migrating bands when
compared to the Hela cell lysate control. The densities of bands from lanes of control (0
gM) and 0.1 gM arglabin-DMA were higher than the rest of the bands and moved faster
than the rest o f the samples. These faster migrating bands may be caused by an uneven
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distribution of electrical voltage o f the gel, or caused by processed RhoA protein (fastermigrating RhoA protein) in control and 0.1 pM arglabin-DMA treated sample. The
densitometry data is shown in figure 36C. The bands from control samples showed the
highest densities. The error bars showed the range from two separate experiments.
After 72 hours incubation with various concentrations of arglabin-DMA or FTI-277,
still only one band was detected in all tested samples (Fig. 37A-B). The migration pattern
o f bands was similar to the 24-hour incubation samples. The bands from 10 pM, 50 pM,
100 pM arglabin-DMA and FTI-277 controls were slower-migrating bands when
compared to the Hela cell lysate control (Fig. 37A-B). The bands from control (0 pM)
and 0.1 pM arglabin-DMA were faster-migrating compared to the Hela cell lysate
control. The densities of bands from two separate experiments were summarized in figure
37C. After 72 hours of incubation, there was no significant density difference between
bands of all samples.
Equal amounts of cellular protein from various treatment groups were utilized in
small GTPase-pull down assays. The complexes of GST-Rhotekin-RBD and active RhoA
protein were selectively eluted from glutathione discs, separated in SDS-polyacrylamide
gel, transferred to a PVDF membrane, and the amounts of RhoA protein determined by
western blot using mouse anti-RhoA monoclonal antibody. When cell lysates incubated
with arglabin-DMA or FTI-277 for 72 hours were used for the pull-down assay, two
bands with the highest densities were found at relative molecular weight o f 40 + 2 kD and
36 + 1 kD, respectively (Fig. 38). The 36 + 1 kD bands were detected in all tested
samples, while the 40 + 2 kD bands were detected in lanes for the control and 0.1 pM, 1
pM, 10 pM and 50 pM arglabin-DMA. The fusion protein of GST-Rhotekin has the
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molecular weight of 36 kD, according to the manufacturer’s guide. The protein with
molecular weight of 40 ± 2 kD could be the dimer of active RhoA protein. This protein
was not found in 100 pM arglabin-DMA and 0.25 pM of FTI-277. These results
indicated that arglabin-DMA and FTI-277 may have inhibited active RhoA formation in
Ras/3T3 cells.
The Effect o f Arglabin-DMA on RhoB Protein in Transformed Cells
Equal numbers o f Ras/3T3 cells were incubated with various concentrations of
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (control) for 24
hours. Cell lysates were generated and the concentrations of cellular protein were
determined by BCA protein assays. Equal amounts of cellular protein were used for
immunoprecipitation with Rabbit anti-RhoB IgG. The eluted material from protein Gagarose beads containing antigen-antibody complex were separated in SDSpolyacrylamide gel, transferred to PVDF membrane, and the amounts of RhoB protein
were determined by Western blot using mouse anti-RhoB monoclonal antibody. The
densities of each band of all tested samples were quantitated using Quantity One
densitometry software from Bio-Rad.
After 24-hour incubation with various concentrations of arglabin-DMA or FTI-277,
two bands from each sample were detected in western blot (Fig. 39A). The band with
significantly higher density was the faster-migrating band (processed RhoB) and the band
with lower density was the slower-migrating band (unprocessed RhoB) (Fig. 39A). The
relative molecular weight of the processed protein estimated from the Precision protein
standard was 21 + 1 kD. The densities of the fast migrating bands quantitated by
densitomety showed no significant difference between all samples (Fig. 39B).
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FIG. 36. Western blot of RhoA after 24-hour incubation with arglabin-DMA or FTI277. The bands from 10 pM, 50 pM, lOOpM arglabin-DMA, and FTI-277 were the slower
migrating bands when compared to the Hela cell lysate control (Fig. 36A-B). The densities
of bands from control (0 pM) and 0.1 pM arglabin-DMA were higher than the rest of
bands and moving faster than the rest of samples. The bands from control samples showed
the highest densities (Fig. 36C).
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FIG. 37. Western blot of RhoA after 72-hour incubation with Arglabin-DMA or FTI277. The bands from 10 gM, 50 gM, 100 gM arglabin-DMA and FTI-277 controls were
slower-migrating bands when compared to the Hela cell lysate control (Fig. 37A-B).
After 72 hours of incubation, there was no significant density difference between bands
of all samples (Fig. 37C).
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FIG. 38. Western blot of RhoA protein after GTPase pull-down assay. When cell
lysates incubated with arglabin-DMA or FTI-277 for 72 hours were used for the pull
down assay, two bands with the highest densities were found at relative molecular
weights of 40 + 2 kD and 3 6 + 1 kD, respectively. The 36 + 1 kD bands were detected in
all tested samples, while the 40 + 2 kD bands were detected in lanes for control and 0.1
pM, 1 pM, 10 pM and 50 pM arglabin-DMA.
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FIG. 39. Western blot o f RhoB after 24-hour incubation with arglabin-DMA or FTI277. The bands with significantly higher density were the faster-migrating bands
(processed RhoB protein) and the bands with lower density were the slower-migrating
bands (unprocessed RhoB protein) (Fig. 39A). The densities of bands quantitated by
densitomety showed no significant difference between all samples (Fig. 39B).
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THE EFFECTS OF ARGLABIN-DMA ON P21/WAF1/CIP1 PROTEIN IN
TRANFORMED CELLS
Equal numbers of Ras/3T3 cells were incubated with various concentrations of
arglabin-DMA (0.1, 1, 10, 50, and 100 |ilM) or 0.25 pM of FTI-277 (control) for 24 hours
and 72 hours. Cell lysates were generated, and the concentrations of cellular protein were
determined by BCA protein assays. Equal amounts of cellular protein were used for
immunoprecipitation using rabbit anti-p21 IgG. The protein G-agarose beads containing
antigen-antibody complex were separated in SDS-polyacrylamide gel, transferred to
PVDF membrane, and the amount of p21/WAFl/CIPl protein were determined by
Western blot using mouse anti-p21/WAFl monoclonal antibody. Direct Western blots
without immunoprecipitation were also performed using equal amounts of cellular
protein. The full-length p21/WAFl/CIPl (SC-4078) from mouse origin produced in E.
coli was used as a positive control for Western blot. The densities of each band of all
tested samples were quantitated using Quantity One densitometry software from BioRad.
After 24 hours incubation with various concentrations of arglabin-DMA or FTI-277,
one major band around 20 kD was detected in all samples (Fig. 40A-C). No significant
density difference was found between samples incubated with various concentrations of
arglabin-DMA (p > 0.05) (Fig. 40D). These data were derived from three separate
experiments. Decreased overall density in the FTI-277 control was found in two of three
experiments.
After 72 hours o f incubation, a trend of increasing density was found from the no
treatment control group to the 100 pM of arglabin-DMA treatment group (Fig. 41A-C).
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Density increased compared to the no treatment control (23 + 5% and 36 + 9% for 50 pM
and 100 pM o f arglabin-DMA treatment groups, respectively) (Fig. 41D). These were the
results from three separate experiments. Decreased densities in the FTI-277 control were
found in all three experiments. This data suggested that arglabin-DMA and FTI-277
affected Ras/3T3 cell cycle by different mechanisms.
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FIG. 40: Western blot of p21AVAFl/CIPl after 24-hour incubation with arglabinDMA or FTI-277. No significant density difference was found between samples
incubated with various concentration of arglabin-DMA (p > 0.05) (Fig. 40A-D). These
data were derived from three separate experiments. Decreased density in lane of FTI-277
control was found in two of the three experiments.
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FIG. 41. Western blot o f p21/WAFl/CIPl after 72-hour incubation with arglabinDMA or FTI-277. A trend of increasing density was found from no treatment control
group to 100 pM of arglabin-DMA treatment group (Fig. 41A-D). Decreased densities in
lanes of FTI-277 control were found in all three experiments.
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DISCUSSION

The most frequently detected alterations in oncogenes in human cancers are
mutations in the ras family of oncogenes (49). The first and most critical posttranslational modification of the Ras protein is famesylation catalyzed by
famesyltransferase (20). Consequently, inhibitors of famesyltransferase have been
proposed as potential agents for treating cancers. Three major groups of
famesyltransferase inhibitors have been developed (20): CAAX pepiddomimetics (such
as FTI-277), heterocyclic FTIs (such as SCH66336), and FPP competitive compounds
(such as FPT inhibitor II). Arglabin-dimethylaminohydrochloride (arglabin-DMA) is
used in current anti-tumor treatments in the Republic of Kazakstan (1, 2, 51).
Shaikenov’s studies showed that arglabin-DMA inhibited the incorporation of
famesylpyrophosphate into H-Ras protein by FTase with an IC50 of 25 pM (51, 52).
Their studies have shown promise in suppressing the growth of various tumor cells by
arglabin-DMA (51, 52). However, the mechanism of arglabin-DMA cytotoxicity and
cytostatic effects on tumor cells at the molecular and cellular level is still unclear. The
current study was undertaken to determine the famesyltransferase inhibitory activity of
arglabin-DMA and to investigate the effects of arglabin-DMA on Ras protein, Rho
protein and cyclin kinase inhibitor p21/WAFl/CIPl.
Based on Shaikenov’s studies, arglabin-DMA inhibits the anchorage-dependent
proliferation and anchorage-independent growth o f neuroblastoma cells at the similar
concentrations (IC50 = 10 pg/mL or 30.5 pM), and inhibits H-Ras transformed cells
(Ras/3T3 cells) at concentration of 2 pg/mL (6.1 pM) (IC50) in the soft-agar colony
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formation assay (52). The present study used a MTT based in vitro toxicology assay kit to
measure metabolic activity of Ras/3T3 cells that were incubated with various
concentrations of arglabin-DMA. The data revealed that the 50% inhibition concentration
of arglabin-DMA for Ras/3T3 cells was 10.34 pM, which is close to the IC50 in the softagar colony formation assay.
Studies of the effect of arglabin-DMA on famesyltransferase showed different results
when using expressed FTase and Ras/3T3 cell lysates. When the FTase assay was
performed using expressed atnd purified FTase, the IC50 for Arglabin-DMA was 2.9 mM,
which was 24,000 times higher than FPT inhibitor II (119 nM). Lineweaver-Burk double
reciprocal plots indicated competitive inhibition of FTase by FPT inhibitor II, and
uncompetitive inhibition of FTase by FTase Inhibitor II and arglabin-DMA. When the
FTase assay was performed using Ras/3T3 cell lysates as a source of FTase, the highest
percentage of arglabin-DMA inhibition was 50-60% compared to the no arglabin-DMA
treatment control, and this inhibition plateaued when the arglabin-DMA concentration
reached 100 nM or higher. These results suggest that arglabin-DMA was transformed in
cells and this transformation was limited by the substrate availability in cells. Data
generated in Shaikenov’s laboratory suggested that arglabin-DMA is transformed by
phosphorylation within cells and that the phosphorylated derivative of arglabin-DMA can
prevent famesylation o f Ras proteins (51). The molecular modeling results from the
present study also indicated that the phosphorylated arglabin-DMA has significantly
higher binding affinity than arglain-DMA alone. Unprocessed arglabin-DMA alone was
not a potent FTase inhibitor. However, a derivative of arglabin-DMA in Ras/3T3 cells
showed inhibitory activity to FTase at nanomolar or higher concentrations, and this
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inhibitory capability was limited by the availability of other substrates that can be used to
transform arglabin-DMA within cells. ATP is a possible substrate based on Dr.
Saikenov’s study.
The Rho GTPases are essential for Ras-induced oncogenic transformation (35) and
activated Rho acts synergistically with activated Raf in cell transformation. Raf, with
activated serine/threonine kinase activity, sends positive signals down a kinase cascade
(the mitogen-activated protein kinase pathway) and prompts cells to move through the G1
phase o f the cell cycle towards S phase (42, 44, 50). Excessive signaling from Ras/Raf
induces p21/W AFl/CIPl, which blocks entry into S phase. RhoA overcomes the cellcycle block by suppressing expression o f p21/WAFl/CIPl (42, 44, 50) (Fig. 3). Although
some evidence showed the involvement of RhoB in the anti-tumor activity of FTIs
(11,17), direct evidence implicating RhoB in the mechanism of action o f FTIs in human
tumors is lacking.
FTIs were originally developed as a Ras-targeted therapy, because Ras protein plays
a crucial role in cellular signal transduction pathways, and the first and most critical posttranslational modification o f Ras is famesylation catalyzed by the FTase (20, 40). Four
isoforms of Ras proteins have been discovered (63). Ki-Ras4A, Ki-Ras4B, and N-Ras
proteins can be either famesylated or geranylgeranylated, whereas H-Ras proteins are
singly famesylated (48, 63). Expressions of H-Ras and K-Ras (including both Ki-Ras4A
and Ki-Ras4B) in Ras/3T3 cells that were incubated with various concentrations of
arglabin-DMA (0.1, 1, 10, 50, and 100 pM) or 0.25 pM of FTI-277 (control) were
examined in this study. Western blots and densitometry showed significant decreases in
the ratio o f processed to unprocessed H-Ras protein in cell lysates incubated with 100 pM
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of arglabin-DMA and cell lysates incubated with FTI-277 for 24 hours and 72 hours.
Western blots o f active H-Ras protein from small GTPase pull-down assays showed
significant reduction of active H-Ras production after incubation with 50 pM of arglabinDMA for 24 hours, or 1 pM of arglabin-DMA for 72 hours. The K-Ras can undergo
geranylgeranylation catalyzed by GGT-I when cells are treated with FTIs (63). Thus,
tumors bearing the mutant Ki-ras4B isoform should be resistant to FTIs; however, some
tumors bearing Ki-ras4B mutations are clearly responsive to FTI treatments. In the
present study, only processed K-Ras protein was detected and no significant density
differences between bands o f all samples were found after 24 hours of incubation with
arglabin-DMA. This result indicated that processing of K-Ras protein was not affected by
arglabin-DMA or FTI-277. Famesylation of H-Ras was affected by arglabin-DMA;
however, this inhibition cannot account for the cytotoxicity of arglabin-DMA alone, since
H-Ras is one o f the four Ras proteins in Ras/3T3 cells and H-Ras is only involved in part
o f Ras signaling pathway. K-Ras was not affected by arglabin-DMA or FTI-277.
Dr. Prendergast and his research team at the Wistar Institute suggested that cell
growth inhibition by famesyltransferase inhibitors is mediated by gain of
geranylgeranylated RhoB (17, 32). Dr. Chen‘s results (11) supported the conclusion that
alteration of RhoB prenylation is both necessary and sufficient to the FTI mechanism in
malignant cells. Both RhoB-F and RhoB-GG induce apoptosis, inhibit oncogenic
signaling, and suppress transformation in vitro and in vivo (11). RhoB proteins can be
either famesylated or geranylgeranylated, whereas RhoA proteins are singly
geranylgeranylated (48, 63). The half-life of RhoB protein is about 2 hours and that of
RhoA protein is around 30 hours. The results of the present study showed that only
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unprocessed RhoA was detected by Western blot after 24 hours or 72 hours of incubation
with 10 pM, 50 pM, lOOpM arglabin-DMA, and FTI-277. There were no significant
density differences between bands of all samples. Western blots of active RhoA protein
from small GTPase pull-down assays showed significant reduction of active RhoA
production after 72 hours of incubation with 50 pM of arglabin-DMA. These results
suggested that production of processed or activated RhoA protein was affected by
arglabin-DMA and FTI-277. In the present study, only processed RhoB protein was
detected and no significant density difference between bands o f all samples was found
after 24 hours o f incubation with arglabin-DMA. This result indicated that processing of
RhoB protein was not affected by arglabin-DMA or FTI-277.
The 21 kD protein o f the WAF1 gene is found in a complex involving cyclins,
CDKs, and proliferating cell nuclear antigen (PCNA) in normal cells but not in
transformed cells and appears to be a universal inhibitor of CDK activity (24). One
consequence o f p21/WAFl/CIPl binding to and inhibiting CDKs is the prevention of
CDK-dependent phosphorylaition and subsequent inactivation o f the retinoblastoma (Rb)
protein that is essential for cell cycle progression (24). P21/WAF1/CIP1 is, therefore, a
potent and reversible inhibitor of cell cycle progression at both the G1 and G2 check
points, presumably to allow sufficient time for DNA repair to be completed (19). Study
of the effects o f arglabin-DMA on cyclin kinase inhibitor p21/WAFl/CIPl protein was
performed using the Ras/3T3 cell line. Equal amounts of protein lysates from Ras/3T3
cells that were incubated with various concentrations of arglabin-DMA (0.1, 1, 10, 50,
and 100 |iiM) or 0.25 pM o f FTI-277 (control) for 24 hours or 72 hours were used to
detect p21/WAFl/CIPl proteins. This study showed a trend of increasing
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p21/WAFl/CIPl production after 72 hours of incubation with arglabin-DMA and this
trend was not found in the FTI-277 control, which suggested a different cellular
mechanism of cytotoxic effect for arglabin-DMA and FTI-277. However, this study only
detected p21/WAFl/CIPl protein in the whole cell lysates, which include the
p21/WAFl/CIPl protein in a complex involving cyclins, CDKs, and proliferating cell
nuclear antigen (PCNA) and p21/WAFl/CIPl protein free in cytoplasm.
In summary, cellular mechanism of arglabin-DMA cytotoxic effect was investigated
in the present study. First, arglabin-DMA itself is not a potent FTase inhibitor, however,
arglabin-DMA was transformed to a derivative in Ras/3T3 cells that can inhibit FTase
activity at nanomolar or higher concentrations, and this inhibitory capability was limited
by the availability of other substrates that can be used to transform arglabin-DMA within
cells. Secondly, H-Ras famesylation, RhoA geranylgeranylation, andp21/W AFl/CIPl
production were affected by arglabin-DMA, while K-Ras prenylation and RhoB
prenylation were not influenced by arglabin-DMA treatments (Fig. 42).
Since geranylgeranylations of RhoB and K-Ras were not affected by arglabin-DMA
and famesylations o f RhoB and K-Ras were inhibited by arglabin-DMA, the balances
between RhoB-F and RhoB-GG or K-Ras-F and K-Ras-GG were disturbed. The half-life
of RhoB is 2 hours and the half-life of K-Ras protein is around 24 hours. This means that
large amounts of geranylgeranyltransferase (GGT) and geranylgeranylpyrophosphate
(GGPP) were used for RhoB and K-Ras prenylation. The half-life of RhoA is around 30
hours, RhoA can only be geranylgeranylated and the availabilities of GGT and GGPP for
geranylgeranylation of RhoA were affected by arglabin-DMA treatments. When H-Ras
protein prenylation was inhibited by arglabin-DMA, K-Ras protein prenylation was not
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affected by arglabin-DMA, the overall signals from Ras to Raf may be reduced, but most
o f signals still existed, which can induce p21/WAFl/CIPl expression. RhoA should
overcome the cell-cycle block by suppressing expression of p21/WAFl/CIPl in normal
circumstances (42, 44, 50), but RhoA geranylgeranylation was inhibited due to lack of
GGT and GGPP after arglabin-DMA treatments. Thus, the increased expressions of
p21/WAFl/CIPl were found after 72 hours treatment of arglabin-DMA. However, this
increasing p21/WAFl/CIPl was not found in FTI-277 treated group, which suggests that
the cellular mechanism o f arglabin-DMA cytotoxic effect is different from the cellular
mechanism o f FTI-277.
Taken together, arglabin-DMA can be transformed to a derivative in Ras/3T3 cells
that will inhibit FTase activity at nanomolar or higher concentrations. The inhibition of
Ras and RhoB protein famesylation will shift more active K-Ras and RhoB proteins to
geranylgeranylated forms after 24 to 72 hours incubation. The availability o f GGT and
GGPP for RhoA geranylgeranylation will be reduced, which can decrease the inhibitory
effect o f RhoA onp21/W AFl/CIPl production. Increasing p21/WAFl/CIPl production
can block Ras/3T3 cells at G 1 phase of cell cycle, thus inhibits DNA synthesis and cell
proliferation. Understanding of the cellular mechanism of arglabin-DMA cytotoxic
effects should help clinicians to determine the dose of arglabin-DMA for treatment and to
use arglabin-DMA in combination with metabolical substrate (such as ATP) in cancer
treatments. Detection o f p21/WAFl/CIPl in tumor cells may be used as a marker of
effectiveness o f arglabin-DMA treatments.
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SUMMARY

Arglabin-DMA itself is not a potent FTase inhibitor, however, arglabin-DMA was
transformed to a derivative in Ras/3T3 cells that can inhibit FTase activity at nanomolar
or higher concentrations, and this inhibitory capability was limited by the availability of
other substrates that can be used to transform arglabin-DMA within cells. H-Ras
famesylation, RhoA geranylgeranylation, and cyclin kinase inhibitor p21 /WAF1/CIP1
production were affected by arglabin-DMA, while K-Ras prenylation and RhoB
prenylation were not influenced by arglabin-DMA treatments.
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APPENDIX A

TABLE 3. Summary of the intermolecular energy between FTase and various ligands
Ligands
Frame 1
Frame2
Frame3
Frame4
Frame5
Frame6
Frame7
Frame8
Frame9
FrametO
Mean

FPP
-61.99
-55.26
-63.97
-72.41
-57.63
-51.59
-62.03
-61.45
-59.42
-62.42
-60.817

Phosphorylated
Arglabin-DMA
-64.62
-64.63
-56.78
-64.95
-64.87
-59.53
-71.19
-57.87
-62.25
-70.14
-63.68

FPT Inhibitor
II
-92.71
-98.13
-91.37
-85.42
-82.74
-85.56
-56.14
-73.81
-71.84
-84.15
-82.19

FPT Inhibitor
III
-86.93
-79.58
-78.42
-82.41
-81.04
-70.68
-84.64
-71.13
-79.31
-74.91
-78.91

FTI277
-82.06
-65.36
-77.49
-68.86
-75.04
-49.38
-60.72
-60.33
-65.53
-54.57
-65.93

FTase
Inhibitor II
-63.61
-48.93
-58.62
-54.61
-46.71
-65.91
-56.76
-69.94
-53.24
-57.43
-57.57

ArglabinDMA
-45.96
-45.45
-45.04
-39.65
-53.86
-49.19
-54.61
-46.93
-42.48
-46.51
-46.97

APPENDIX B

TABLE 4. Statistical evaluation of the binding affinity between FTase and various
ligands. ANOVA single factor. Probability level: 0.05
Groups
FPP
Phosphorylated Arglabin-DMA
FPT Inhibitor II
FTI-277
FPT Inhibitor III
FTase Inhibitor 11
Arglabin-DMA

Count
10
10
10
10
10
10
10

Sum
-608.17
-636.83
-821.86
-659.34
-789.03
-575.73
-469.68

ANOVA
Source of Variation
Between Groups
Within Groups

SS
8889.07964
3691.43608

df
6
63

Total

12580.51572

69

Average
-60.817
-63.683
-82.186
-65.934
-78.903
-57.573
-46.968

Variance
30.92033444
22.62002333
147.8554711
105.2587156
28.78446778
53.41153444
21.30901778

MS
F
P-value
1481.51327 25.28428888 4.693E-15
58.5942235
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